Claudio Cerchione

Claudio Cerchione, MD, PhD - Napoli, 19/02/1984

Current Position: Dirigente Medico ricercatore – Phase 1 Trials Board - Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola (FC), Italy

Work E-mail: claudio.cerchione@irst.emr.it [mailto:claudio.cerchione@irst.emr.it]

University: Adjunct Professor – Department of Pharmacology and Biotechnology – University of Bologna

Memberships:

EMA Scientific Advisory Group Onco-Hematology – Board Member

President of Society of Hematologic Oncology (SOHO) Italy

Ambassador of SOHO (Society of Hematologic Oncology)

ASH (American Society of Hematology)

EHA (European Society of Hematology)

EMN (European Myeloma Network)

SIE (Società Italiana di Ematologia)

SIES (Società Italiana di Ematologia Sperimentale)

AIL (Associazione Italiana contro le Leucemie, Linfomi, Mielomi)

AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica)

ACLTI (Associazione contro le Leucemie e i Tumori dell’Infanzia)

Rotary Club

 

Career

Degree in Medicine, University Federico II, Napoli, Italy, 110 cum laude, July 2008 (Final thesis in Hematology–New TKI in CML)

Professional Medical Qualification: 270/270, February 2009, School of Medicine – University Federico II, Naples, Italy

Fellowship Program: Hematology, 50 cum laude, July 2014, University Federico II, Naples, Italy

PhD Program: Newer biomedical and Surgical treatments, Department of Clinical Medicine and Surgery - University Federico II, Naples, Italy (Tutor prof Fabrizio Pane - Director prof Giovanni Di Minno) - Ottimo cum laude, May 2017, University Federico II, Naples, Italy

European Hematology Exam (EHA - European Society of Hematology), 12 June 2018

Accreditation JACIE since 2018

Home care doctor in Adult Hematology (since November 2014)

Home care doctor in Pediatric Hematology (since May 2015)

Scientific Responsible of ACLTI (Associazione contro le Leucemie e i Tumori dell’Infanzia)

ASL Napoli 1 (also Secondigliano Jail, Naples) (September 2011 – June 2014)

Pediatric OncoHematology A.O.R.N. Santobono-Pausilipon Hospital July 2014 – August 2018

Ambassador of Society of Hematologic Oncology (SOHO) – MD Anderson Cancer Center for Italy, since 2019 (Responsible Prof. H. Kantarjian)

Memberships:

1. AIL (Associazione Italiana contro Leucemie-Linfomi-Mielomi) since 2009
2. SIE (Società Italiana di Ematologia) since 2009
3. SIES (Società Italiana di Ematologia Sperimentale) since 2016
4. EHA (European Hematology Association) since 2009
5. AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) since 2015
6. SOHO (Society of Hematologic Oncology) since 2017, Ambassador since 2019
7. ASH (American Society of Hematology) since 2017
8. ACLTI (Associazione contro le Leucemie e I Tumori dell’Infanzia) – Scientific Responsible – since 2017
9. Rotary Club – since 2017
10. EMN (European Myeloma Network) – Italy – Board member of relapsed/refractory panel
11. EMN (European Myeloma Network) – Europe – Board member since 2019
12. SOHO (Society of Hematologic Oncology) Italy – President and Founder since 2019

Work experiences

2018 - Today: “Dirigente Medico” in Hematology – IRST IRCCS Meldola (FC) – Italy (included in Phase 1 board)

Winner of Clinical Research Training in Hematology (CRTH) – European Hematology Association (EHA) 2018/2019

 

International Experiences:

2019 – Today: Clinical and Research Collaboration with Leukemia Department of MD Anderson Cancer Center and Ambassador for Italy of Society of Hematologic Oncology (SOHO) (Director Prof H. Kantarjian - Houston, Texas, USA)

2009: Visitor Medical Student (Clinical Clerkship) – Research and clinical activities in Hematology Department, Hospitais da Universidade de Coimbra (Director prof Adriana Teixeira), Portugal

2005-2006: Visitor Medical Student (Erasmus project) – Research and clinical activities in Hematology Department, Friedrich-Wilhelms Universitat Bonn (Director prof Schmidt Wolf), Germany

Clinical investigation

Co-responsible [during PhD program] in clinical trial for Acute Leukemias performed in Hematology Division, Federico II, Naples, Italy (Front-line central vascular access devices in acute leukemias – peripherally inserted catheter (PICC) versus traditional venous catether (CVC) : a phase IV randomized trial (NCT02405728)

Partecipation in RECAMDS (Regional Myelodysplasic Syndromes Register)

Sub-investigator of following clinical trial (GCP Training: 15/06/2011, University Federico II, Naples, Italy):

• ●“MORE” –Revlimid/Lenalidomide in del 5q syndrome (Celgene)
• ●Denosumab in Multiple Myeloma (AMGEN)
• ●Pegilated GCSF in LNH (TEVA)
• ●GOYA (LNH, ROCHE)
• ●TOWER-AMG103 (Blinatumomab in LLA)Responsible of Compassionate Use Program for new drugs in Multiple Myeloma:

  Principal Investigator of following clinical trials (IRST IRCCS Meldola (FC)):

• A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma (Phase 1 – NCT03486067)
• DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma (Phase 3 - NCT04246047)
• A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia (Phase 3 - NCT03616470)
• EFC15992/ITHACA: A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma (Phase 3 - NCT04270409)
• A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (Phase 3 - NCT03173248)
• Phase 1-2 trial evaluating anti-TGFbeta agent (SAR439459) or pomalidomide in combination with isatuximab and dexamethasone in relapsed or refractory multiple myeloma (Phase 1 - ACT16482)
• M20-258: A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (Phase 1 - NCT04570631)
• SKY92 plus Integrated Multidisciplinary approach to detect New Prognostic Index in Multiple Myeloma (SIMPI)
• KCP-8602-801 – Eltanexor in Myelodysplastic syndromes
• DREAMM-9 – Phase 1 - Belantamab plus bortezomib-lenalidomide-dexamethasone in transplant-ineligibly newly diagnosed multiple myeloma
• MagnetisMM-7 - C1071007 – Phase 2 - Elranatamab (PF-06863135) versus lenalidomide in maintenance after autologous stem cell transplantation
• MagnetisMM-5 – Phase 3 - Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
• MAJESTEC-3 - 64007957-MMY3001 – Phase 3 – Teclistamab plus Daratumumab versus Dara-pom-dexa or dara-bortezomib dexa in relapsed/refractory multiple myeloma
• EFC15951 – Phase 3 - Isatuximab subcutaneous versus endovenous in combination with poma-dexa in relapsed-refractory multiple myeloma
• CA057-008 – Phase 3 - CC92480 plus KD versus KD in relapsed-refractory multiple myeloma
• M17-072 Phase 3 - stopped
• M22-947 – Phase 1 – ABBV-383 plus PomDex/LenDex/DaraDex or Nirogacestat in relapsed-refractory myeloma
• EMN29 – Phase 3 - Selinexor-pom-dexa versus Elotuzumab-pom-dexa in relapsed/refractory multiple myeloma
• TAK-573-1502 – Phase 1b – Modakafusp alfa in combination therapy in relapsed/refractory multiple myeloma
• CC-220-MM-001 – Phase 1b/2 CC-220 in monotherapy or combination in multiple myeloma

  Observational Trials

• Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting B-cell Lymphoma 2 (BCL-2) (NCT04070807)
• A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment (NCT04035226)
• ABVD vs BEACOPP in HL
• StreaMMing,
• Impact of novel agents in clinical management in real world of hematological malignancies (IRST),
• Impact of novel agents in clinical management in real world of Multiple Myeloma (IRST),
• Prospective Comparison between whole body MRI plus FDG-PET/CT and FDG-PET/CT in Multiple Myeloma (IRST)
• Protocollo SEIFEM Prospettico sulle Complicanze Infettive in pazienti trattati in prima linea con Demetilanti da soli o in associazione con Venetoclax o altri farmaci.
• Studio osservazione SEIFEM Vyxeos
• EMN COVID
• EMN - Real-life use of Carfilzomib, lenalidomide and desamethasone (KRd)
• A retrospective and prospective multicentre observational study for the evaluation of incidence of familial AML/MDSs in patients with myeloid neoplasms (AML/MDS)”
• MUST (Multiple Myeloma Italian ObServational sTudy)

  Sub-investigator of many clinical trial (IRST IRCCS Meldola (FC)), some of which are:

• PAC203
• EMN17 - Perseus
• UNITO-MM01 - Forte (Multiple Myeloma)
• Real MM
• FIL-ROUGE
• Triangle
• PCYC-1143CA
• FOLL-12
• Citadel 204
• V-RBAC
• ACE 006
• ACE-CL-007
• RV-MM PI-0752

Fields of interest and research

• Clinical management and research on Multiple Myeloma and MGUS, with particular interest in imaging diagnostic techniques, alternative chemotherapy regimens in relapsed/refractory patients and transplantation procedures,
• Clinical management and research on Acute Lymphoblastic and Acute Myeloid Leukemia with particular interest in alternative chemotherapy regimens in relapsed/refractory patients,
• Clinical management and research on Chronic Myeloid Leukemia and Ph- Myeloproliferative neoplasms, with research interest on mechanisms of second generation TKIs.
• Clinical management and research of Myelodysplastic Syndromes and Acute Leukemias, with particular interest on role of demethylating agents.
• Clinical management and research of Hodgkin and non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
• Clinical management and research of Pediatric Acute Leukemias
• Clinical management and research of Infections in Hematologic patients, with particular interest in diagnostic tools and imaging techniques, especially for invasive fungal infections
• Clinical management and research of Myelodysplastic Syndromes and Acute Leukemias, with particular interest on role of demethylating agents.
• Clinical management and research of Autologous and Allogenic Bone Marrow Transplantation (JACIE Certificate)

Education and training

15 May 2017

Ph.D., Hematology Division, University of Naples, Italy, with full marks, cum laude.

30 June 2009

Residency in Hematology, University of Naples, Italy, with full marks, cum laude.

22 July 2002

M.D., University of Naples, Italy, with full marks, cum laude.

Personal skills and competences

Native Speaking: Italian

Other languages_

English (Certificate C1.2 British Council, Naples, Italy)

German (Certificate B2, Rheinische Friedrich-Wilhelms Universitat, Bonn, Germany)

Personal skills and competences

Computer skills and competences: Excellent knowledge of Office packages (Word, Excel, Power-point), Internet Explorer, Google Chrome, Mozilla Firefox and E-mail client (Outlook express), Operating systems (Microsoft Windows and Mac OS)

User of statistical program (STAT v7, SPSS).

Driving licence: European Driving license, type B

BLSD (Basic Life Support early Defibrillation) (17/07/2010 - AOU Federico II – Napoli – Italy; 20/09/2018 – IRST IRCCS – Forlimpopoli)

P.T.C. (Pre-Hospital Trauma Care) (18/09/2010) AOU Federico II – Napoli - Italy

BLSD (Basic Life Support Early Defibrillation) (20/09/2018) IRST – IRCCS – Meldola (FC) – Italy

ALS (Advanced Life Support) (22-23/03/2019) IRST – IRCCS – Meldola (FC) – Italy

Teaching

Research Teaching Assistant (“Cultore della materia”) in Hematology - University of Ferrara, Italy

1. Medicine and Surgery

Research Teaching Assistant (“Cultore della materia”) in Hematology - University Federico II, Naples, Italy

1. Medicine and Surgery
2. Biotechnology
3. Laboratory techicians
4. Radiology technicians

Advisory Board/Consultant

1. Multiple Myeloma
2. Acute Myeloid Leukemia
3. Acute Lymphoblastic Leukemia
4. Waldenstrom Disease
5. Chronic Lymphocytic Leukemia

Member of Scientific Committees

1. EUBEA
2. Proeventi

International and National Awards

1. Winner of Clinical Resarch Training Program in Hematology (European Society of Hematology - EHA) 2018/2019
2. Travel Grant winner at the 8th Stem Cell Course- Collegio Ghislieri, Pavia
3. Travel Grant winner at the 9th Stem Cell Course- Collegio Ghislieri, Pavia
4. Travel Grant winner at the 10th Stem Cell Course- Collegio Ghislieri, Pavia
5. Travel Grant winner at the 11th Stem Cell Course- Collegio Ghislieri, Pavia
6. Travel Grant winner at the 12th Stem Cell Course- Collegio Ghislieri, Pavia
7. Travel Grant winner at the 13th Stem Cell Course- Collegio Ghislieri, Pavia
8. iAcademy Award 2013 – Napoli
9. Travel Grant winner at Brain training in Hematology: Casi clinici stimolanti e allocuzioni lungimiranti 2013 (Italian Society of Hematology, Pesaro, Italy)
10. iAcademy Award 2014 – Napoli
11. Travel Grant winner at Corso Innovazioni in Ematologia 2014 (Italian Society of Hematology, Pesaro, Italy)
12. Winner of Progressi in Ematologia – I giovani come protagonisti - SIE Giovani (Stazione Marittima, Napoli)
13. Travel Grant winner at the 15th Stem Cell Course- Collegio Ghislieri, Pavia
14. Travel Grant winner at Ematologia nel 2015: come sta cambiando la musica (Italian Society of Hematology, Pesaro, Italy)
15. Travel Grant winner at SIES (Società Italiana Ematologia Sperimentale) congress 2016, Rimini
16. Travel Grant winner at Nuovo Cinema in Ematologia 2016 (Italian Society of Hematology, Pesaro, Italy)
17. Travel Grant winner at Novità in Ematologia, Modena, Italy
18. Travel Grant winner (with Oral Comunication) at EHA 2017, Madrid
19. Travel Grant winner at SOHO 2017, Houston, Texas, USA
20. Travel Grant winner at Springer Rising Medical Stars – High Formation Program, Milan, Italy
21. Rotary Club Volunteer prize 2018
22. Travel Grant winner at SOHO 2018, Houston, Texas, USA
23. Travel Grant winner at SIES (Società Italiana Ematologia Sperimentale) congress 2018, Rimini
24. Travel Grant winner at EHA 2020

Editorial Board Membership

1. Associate Editor in Frontiers in Oncology
2. Associate Editor in Supportive Care in Cancer
3. Associate Editor in Turkish Journal of Hematology
4. Associate Editor in Hematology Reports
5. Associate Editor in Journal of Clinical Medicine
6. Associate Editor in Frontiers in Hematology
7. Guest Editor in Minerva Medica
8. Guest Editor in Panminerva Medica
9. Guest Editor in International Journal of Molecular Sciences
10. Guest Editor in Cancer Drug Resistence

Grant rewiever Board Member

From 25/08/2022 – today: Board member of the Clinical Research Expert Review Panel, which serves CRUK's Clinical Research Committee (CRC), Cancer Research UK

From 15/11/2022 – today: Board member of the Expert Board of the Czech Health Research Council for Evaluation of Project Proposal

Oral presentations national and international events:

1. Successful pregnancies in Chronic Myeloid Leukaemia male patient on Imatinib therapy

   Annual meeting of “Centri di Ematologia Meridionale ed Insulare” (SIE SUD), 28-29 October 2010, Castellaneta Marina (Taranto, Italy)

2. Renal failure associated to tyrosine kinase inhibitors

   Annual meeting of “Centri di Ematologia Meridionale ed Insulare” (SIE SUD), 28-29 October 2010, Castellaneta Marina (Taranto, Italy)

3. Monitoraggio dei livelli plasmatici degli antimicotici azolici nei pazienti neutropenici e correlazioni con efficacia terapeutica ed effetti tossici

   Under40 Project in Hematology, 15-16 November 2012, Napoli, Italy

4. Terapia combinata con voriconazolo e caspofungina: una nuova arma contro l’Aspergillosi invasive

   iAcademy Award 2013 – 22 November 2013, Napoli, Italy

5. Ruolo della Bendamustina nel paziente con Mieloma Multiplo Recidivato e Refrattario

   Policlinico AOU Federico II – 3 April 2014, Napoli, Italy

6. Analisi della risposta agli agenti eritrostimolanti in una coorte di pazienti affetti da syndrome mielodisplastica low-risk afferenti al Registro Campano per le MDS

   Italian Red Cell Club 2014 – 3-4 October 2014, San Marcellino e Festo – Napoli, Italy

7. Efficacia del Voriconazolo nell’aspergillosi refrattaria alla terapia con amfotericina B : la nostra esperienza

   iAcademy Award 2014 – 27 November 2014, Avellino, Italy

8. Lo Sportello Giovani dell’Ordine dei Medici di Napoli incontra i Medici in Formazione 2014/2015 (2 March 2015, Policlinico Federico II, Napoli)
9. Mieloma Multiplo: Strategie a confronto: Switch: bilancio tra sostenibilità ed efficacia
   • 23April 2015, Hotel Royal – Napoli
10. Il mielodisplastico alto rischio: ruolo degli agenti ipometilanti

    La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – II Edizione – 4 June 2015, Hotel Montespina, Napoli

11. Il mielodisplastico non trasfusione dipendente: ruolo dell’Epoietina

    La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – II Edizione – 4 June 2015, Hotel Montespina, Napoli

12. Mieloma Multiplo – Winner of Progressi in Ematologia I giovani come Protagonisti - 4-5 marzo 2016, Napoli
13. Il Mieloma Multiplo: innovazioni nei trattamenti di prima linea e linee successive

    La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – III Edizione – 16 June 2016, Hotel Montespina, Napoli

14. Il mielodisplastico non trasfusione dipendente: ruolo dell’Epoietina

    La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – III Edizione – 16 June 2016, Hotel Montespina, Napoli

15. L’esperto risponde – Training a field force – Riunione di ciclo AMGEN

    15 September 2016 - Fortevillage – Santa Margherita di Pula (Cagliari)

16. Mieloma Multiplo - Esperienze di pratica clinica: dalle opzioni terapeutiche alla strategia terapeutica

    Il Mieloma Multiplo - 5 May 2017, Hotel Royal, Napoli

17. Il trattamento del Mieloma Multiplo recidivato-refrattario

    Il valore dell’immuno-oncologia nel Mieloma Multiplo, 6 June 2017, Tavola Rotonda BMS, Policlinico Federico II, Napoli

18. Il trattamento medico dell’anemia nella pratica clinica con Epoietina

    La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – IV Edizione – 15 June 2017, Hotel Montespina, Napoli

19. Il Mieloma Multiplo: innovazioni nei trattamenti di prima linea e linee successive

    La gestione delle alterazioni della crasi ematica e delle tossicità da chemioterapia: confronto tra esperti – IV Edizione – 15 June 2017, Hotel Montespina, Napoli

20. Front-line vascular access devices in acute leukemias – Peripherally inserted central catheter (PICCs) versus traditional central venous catheter (CVCs): a phase IV randomized trial (NCT02405728)

    Oral comunication - European Hematology Association (EHA) 2017, 24 June 2017, Madrid, Spain

21. L’immunoterapia: una tripletta differente - Il Mieloma Multiplo: dalla prima linea alla recidiva – 30 September 2017, Naples, Italy
22. Front-line vascular access devices in acute leukemias – Peripherally inserted central catheter (PICCs) versus traditional central venous catheter (CVCs): a phase IV randomized trial – an update (NCT02405728)

    Oral comunication – Italian Society of Hematology 2017, 16 October 2017, Roma, Italy

23. Leucemia Mieloide Cronica – l’ingresso in clinica dei generici: opportunità e preoccupazioni. La Medicina Narrativa nell’era della Precision Medicine – Le Medical Humanities in Ematologia, Oncologia e Terapia del dolore – 10 November 2017, Sala Convegni Croce Rossa Italiana, Naples, Italy
24. L’approccio terapeutico nel Mieloma Multiplo – Nuovi scenari in Ematologia, 1 December 2017, Palazzo Esedra, Naples, Italy
25. Lenalidomide in Mantle Cell Lymphoma Patients and MRD status in MRD: clinical impact in hematological maligancies – School of NGS - 7 September 2018 - IRST IRCCS Meldola (FC)
26. Training Ixazomib in Multiple Myeloma – Takeda Italia – Roma + Bologna, 12 September, 10 October 2018
27. Moderatore Sessione “Registry, big data and interpretation” in “Nuove frontiere del NGS nella diagnostica ematologica” - 25 October 2018 – IRST IRCCS Meldola (FC)
28. Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

    Oral comunication – Italian Society of Experimental Hematology 2018, 18 October 2018, Rimini, Italy

29. Relatore “IMIDs e la modulazione del microambiente nel Mieloma Multiplo: le nuove indicazioni della Lenalidomide e nuove opportunità della Polmalidomide” in “L’ematologia, l’Oncologia e la medicina del dolore tra umanizzazione delle cure e precision medicine” – 26 October 2018 - Sala Convegni Croce Rossa Italiana – Napoli
30. Scientific Responsible of First Master in Pediatric OncoHematology – A.O.R.N. Santobono-Pausilipon – Napoli – 2018/2019 – Talks 1) Introduzione al Master e all’Ematologia Pediatrica, 2) Diagnostica delle patologie ematologiche, 3) Terapia di supporto nel bambino emopatico – Il ruolo dei fattori di crescita
31. Perceptorship Training Program – Optimizing Outcomes for Patients with Acute Lymphoblastic Leukemia – International Faculty Member + Speaker – 16-17 January 2019 – MD Anderson Cancer Center (Houston, Texas, USA)
32. Iron deficiency in neonatology and pediatrics: State of the art - International Multidisciplinary Course on Iron Deficiency (IMCID) – 8-9 March 2019 – NH Collection Roma Vittorio Veneto –Rome, Italy
33. DLI plus Immunotherapy in ALL - XI International Florence meeting on Hematology – Focus on treatment in difficult scenarios – 4-5 April 2019 – Rettorato University of Florence – Florence, Italy
34. Keynote speech – Report sulla recente Conferenza di Chicago della Società Americana di oncologia clinica (ASCO) - III Convegno nazionale della rete oncologica – SIFACT (Società italiana di farmacia clinica e terapia) – 7-8 June 2019 – Centro Congressi SGR - Rimini, Italy
35. Session Chair in New Drugs in Hematology – 28 June 2019 – Palazzo Alabardieri, Napoli, Italy
36. Gestione della tossicità delle nuove opzioni terapeutiche - Gruppo di miglioramento (FSC) Nuove prospettive nel campo della Leucemia Linfoblastica Acuta – 4 July 2019, Hotel Baglioni, Firenze,
37. President and Scientific Board in SOHO 1st Italian Conference, Session Chair in New Drugs in Acute Myeloid Leukemia (Session Chairs: C. Cerchione, H. Kantarjian) Talk: Environment-mediated drug resistance in AML; Session Chair in The near future of Multiple Myeloma and MGUS (Session Chairs: C. Cerchione, H. Lee) Talk: Multiple Myeloma: State of the art in Italy; 25-26 September 2019, Crowne Plaza St. Peter’s, Roma:
38. Focus sulla malattia di Gaucher – I Master in Ematologia Pediatrica (Presidente e Responsabile Scientifico) –5 October 2019, Osp. Pausilipon, Napoli,
39. Prima linea terapeutica nel Mieloma Multiplo - Post ASCO-ESMO 2019 – 11-12 October 2019, Rocca delle Caminate, Meldola (FC)
40. Hematologic Malignancies, Chair in Multiple Myeloma Session – 17-18 October 2019, Hotel Savoia, Rimini
41. L’ematologia, l’oncologia e la medicina del dolore tra umanizzazione delle cure e precision medicine – 24-25 October 2019, Napoli,
42. Advisory Board ReMMap, IQVIA – 30 October 2019, IQVIA, Milano
43. Italian Investigator meeting Avalon Trial – 5 November 2019, Hotel Michelangelo, Milano,
44. Carfilzomib-Lenalidomide-Dexamethasone in the management of Lenalidomide-refractory Multiple Myeloma - Under40 in Hematology – 7-8 November 2019, Hotel Ramada, Milano,
45. Pomalidomide-Dexamethasone in the management of heavily pretreated Multiple Myeloma - Under40 in Hematology – 7-8 November 2019, Hotel Ramada, Milano,
46. CAR-T nelle neoplasie ematologiche – Stato dell’arte: il futuro è oggi – I Master in Ematologia Pediatrica (Presidente e Responsabile Scientifico) – 9 November 2019, Osp. Pausilipon, Napoli
47. Il futuro dell’oncoematologia pediatrica– I Master in Ematologia Pediatrica (Presidente e Responsabile Scientifico) – 9 November 2019, Osp. Pausilipon, Napoli,
48. Advisory Board – Myelodysplastic Syndromes (MDS) Advisor Channel – 11-13 November 2019,
49. Multiple Myeloma: State of the art in Italy - A night with the hematologists – 12 November 2019, Sala Tison IRST, Meldola (FC)
50. Theapeutic approaches in LLA: How to integrate Inotuzumab in the current paradigm? Reuniao Anual Sociedade Portuguesa de Hematologia – 14-15-16 November 2019, Altice Forum, Braga, Portugal
51. AIL Pazienti Leucemia Mieloide Acuta – Seminario Pazienti – Medici, 23 November 2019, Hotel Uappala, Pesaro,
52. Esperienze cliniche e confronto “How I treat” - Leucemia Linfoblastica acuta: Sfide della real life – 26 November 2019, Bianca Maria Palace Hotel – Milano
53. Chair and Speaker (Multiple Myeloma: State of the art in Europe + Theapeutic approaches in LLA: How to integrate Inotuzumab in the current paradigm?) Third Annual European Global Summit on Hematological Malignancies – 13-15 February 2020, Lisbon, Portugal
54. Advisory Board “Belantamab Mafodotin: dati DREAMM-2” – 14 May 2020, Virtual
55. Advisory Board “Algoritmi di trattamento nel MMRR: temi di pratica clinica e subset di pazienti” – IQVIA – 10 July 2020, Virtual
56. Chair in Acute Lymphoblastic Leukemia – State of the art - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
57. Chair in Acute Lymphoblastic Leukemia – Beyond ALL and near future - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
58. Chair in Selected Oral Presentations - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
59. Long term data from Pivotal Trials - CPX-351 in High Risk AML: from bench to bedside - JAZZ Pharmaceuticals Lunch Symposium- 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
60. Environment-mediated drug resistance in AML - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
61. Chair (with M.V. Mateos) in Multiple Myeloma – Hot topics in novel agents era - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
62. Chair (with K.C. Anderson) in Multiple Myeloma – State of the art - 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
63. Multiple Myeloma – State of the art in Europe- 2nd SOHO Italian Conference – A.Roma Lifestyle Hotel – 22-24 September 2020
64. Case based discussion: Introducing Inotuzumab in day to day practice – 9th Annual Acute Leukemia Meeting - 23-26 September 2020, Virtual
65. Janssen CAR-T Referral Centre Physician Advisory Board October 2020 – 14 October 2020, Virtual
66. PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE (Oral Comunication) – SIES XVI – Napoli – 15-17 October 2020
67. Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma: old/new in novel agents’era. XIth Eurasian Hematology Oncology Congress (EHOC) 2020 – 21-24 October 2020 – Virtual
68. La terapia del Mieloma Multiplo recidivato/refrattario – Nuove sfide in Ematologia – 26-28 October 2020, Virtual
69. Overcoming Environment-Mediated Drug Resistance in AML – 29-30 October 2020 - EUROLEUK 2020 – Virtual
70. Advisory Board Virtuale - WEB MEETING - EMILIA ROMAGNA, 11 November 2020 - Mieloma Multiplo 11 November 2020, Virtual
71. La malattia minima residua - Italian Leukemia Summit – 27-28 November 2020, Virtual
72. Advisory Board – Il senso delle parole – Un’altra comunicazione è possibile – 1 December 2020, Virtual
73. Present and future of management of relapsed/refractory Multiple Myeloma + Responsabile Scientifico - 1st SOHO Italy Clinical and Biological School of Multiple Myeloma – 15-16-17 December 2020, Virtual
74. Report studio AVALON – Nuovi approcci terapeutici nella leucemia mieloide acuta – ACCMED - 17 December 2020 – Virtual
75. The frequency of monitoring during TFR - Discutendo di leucemia mieloide cronica, dalla strategia terapeutica alla comunicazione scientifica 3.0 10/03/2021 – Virtual Conference
76. 1st SOHO Italy School of Acute Leukemia – Clinical and Biological - Presidente, Scientific Committee, Speaker and Chair (Talk: Environment mediated drug resistance in AML) – 15-16-17/03/2021
77. Bite bispecific T cell engager: a “new kid in town”– Virtual Conference Multiple Myeloma - 29/03/2021 – IRST IRCCS Meldola (FC),
78. FISH e citogenetica - Sardinian Myeloma Academy 21/05/2021 – Virtual Conference;
79. CASES Europe Insights Into AML 21/05/2021 – Virtual conference;
80. How I manage Multiple Myeloma in 2021 - Post COMy-TianQingHematology IMiDs Summit Forum – 16/06/2021 Cina – Virtual Conference;
81. Multilab: riflessioni sulle principali esperienze cliniche condivise nei workshop “Clinical practice sul Mieloma Multiplo” + Praticamente Ixazomib: presentazione e discussione di casi clinici interattivi 17/06/2021 – Virtual Conference;
82. Approcci terapeutici nel Mieloma Multiplo - Mieloma Multiplo: dalla diagnosi alla valutazione della malattia minima residua 17/06/2021 – Virtual Conference;
83. Congress Connect: Chronic Lymphocytic Leukemia (EHA & ICML 2021) – Speaker – 29 June 2021
84. Progetto Il senso delle parole - Luglio 2021
85. Extracellular vesicles and their role in patients with Multiple Myeloma - Presidente, Scientific Committee, Speaker and Chair (Talk: How I manage relapsed/refractory Multiple Myeloma) 01/07/2021 – Virtual Conference:
86. Advisory Board Meeting Virtuale CAR-T Celgene - 14 July 2021 - Virtual
87. Pratica Clinica MM Open Discussion 02/09/2021 – 03/11/2021 – Virtual Project
88. La carenza di ferro: esperti a confronto sulla best practice - Il ruolo della terapia marziale nel trattamento delle patologie oncoematologiche: stato dell’arte 16-17/09/2021 Bussolengo (VR):
89. Expert Insights on Evolving MM Treatment Practices and Collaborative Patient Management – 24 September 2021 – Virtual
90. 3rd SOHO Italy Annual Conference – Presidente, Scientific Committee, Speaker and Chair (Talks: How I treat relapsed/refractory Multiple Myeloma in Europe; Multiple Myeloma: State of the art in Europe; New frontiers in overcoming; Environment-Mediated Drug Resistance in AML) - 27-30/09/2021 – Rome, Italy
91. Targeting IDH - 10ª Acute Leukemia Meeting – Speaker - 30 september - 2 October, 2021, Madrid, Spain
92. Tra Clinica e Terapie: l’importanza delle nuove tecnologie per diagnosi e monitoraggio della malattia minima residua – Mieloma Multiplo - NGS School - Utilizzo nuove tecnologie NGS a supporto della diagnostica molecolare – Speaker - 4 October 2021 – Piacenza
93. Lancio Daratumumab – Chair - 8 October 2021 – Virtual
94. Acute Lymhoblastic Leukemia (Ph negative) - International Symposium on New Biological insights and novel drugs in Acute Leukemia – Chair - 12-13 October 2021 – Venice, Italy
95. Quando i monoclonali non funzionano più e non posso fare le car-T: cosa scelgo per il mio paziente con mieloma refrattario? - Ematologia nel 2021: tra miti, fake news e realtà – Speaker - 18-19 October 2021 – Pesaro
96. PEGFILGRASTIM VERSUS FILGRASTIM NELLA TERAPIA DI SUPPORTO DEL MIELOMA MULTIPLO PLURITRATTATO IN TERAPIA CON POMALIDOMIDE-DESAMETASONE (Comunicazione orale selezionata) - 48° CONGRESSO NAZIONALE SIE - 16° CONGRESSO NAZIONALE SIES - Milano, Mi.Co - 24-27 October 2021
97. La quantità di IgM può identificare alla diagnosi i pazienti affetti da linfoma di Hodgkin a cattiva prognosi: risultati di uno studio monocentrico retrospettivo (Comunicazione orale selezionata) - 48° CONGRESSO NAZIONALE SIE - 16° CONGRESSO NAZIONALE SIES - Milano, Mi.Co - 24-27 October 2021
98. Importance of Mınımal Residual Diesease Detection in AML Treatment – XII. EURASIAN HEMATOLOGY ONCOLOGY CONGRESS (EHOC) 2021 - 10-13 November 2021 – Istanbul
99. NhetYou – 5 October + 30 November 2022 – Virtual project
100. Workshops Comunicazione di Venetoclax in AML – 29/10/2021 – Bologna
101. ATMP Council Advisory Board Meeting – from November 2021
102. Publish or perish - Novel translational approaches in hematological malignancies: from bench to bedside – Speaker + Chair - 5-6 November 2021 – Catania, Italy
103. La Gestione del paziente con LMA – Speaker - 17 November 2022 + 18 February 2022 – Virtual
104. Advisory Board Abbvie – 26/11/2021 – Bologna
105. Presentazione della Carta dei diritti dei pazienti con mieloma multiplo - 2 December 2021 – Rome
106. Railing the Routes – Roundtable - Rispondere al medical need del paziente: una sfida multidisciplinare?3 December 2021 – Bologna
107. Differenziation Syndrome - Servier LPV conference – Chair + Speaker - 18 November 2021 – Virtual
108. How to improve the HSCT performance and eligibility of the patients with the new drugs? - The AML setting - Targeted therapy in Acute Leukemia in the context of HSCT package – Speaker - 17 December 2021 – Ancona
109. Restart GSK – 17-19 January – Chair – Virtual
110. Post-ASH 2021 iwAL Virtual Meeting – Chair - 21 January 2022 – Virtual
111. Sino-EU PerMed: Invitation to Stakeholders' Workshop – Chair + Speaker 16-17 February 2022 – Florence, Italy + Virtual
112. Pazienti in trattamento con Belantamab – Breakout Rooms - BeBold – Speaker - 14-15 March 2022 – Milan, Italy
113. Opinions in Acute Myeloid Leukemia: An Interactive Local Workshop – Speaker – 15 March 2022 – Virtual
114. Expert Focus in Hematology – IOV Castelfranco Veneto (TV) – Chair – 17 March 2022
115. How I Manage Frontline Multiple Myeloma: State of the Art in Europe + How I Manage Relapsed/Refractory Multiple Myeloma: State of the Art in Europe – Chair + Speaker - 9th Eurasian Hematology-Oncology Summit – 7-8 May 2022 – Istanbul – Turkey
116. MM Units – 26 April - 7 July 2022 – Virtual + Meldola
117. IQVIA Pharma Academy: ATTESTATO Seminario "Good Clinical Practice" – Chair + Speaker - 27-28 April 2022
118. Workshop educazionale “on web” Recenti updates e approcci traslazionali nel Mieloma Multiplo – Chair – 17 May 2022 – Virtual
119. Il Ruolo dell’MRD nella scelta terapeutica del Mieloma Multiplo - Tecnologie innovative per la misurazione della malattia residua – Chair e Speaker - 24 May 2022 – Bologna, Italy
120. How I treat Multiple Myeloma in Europe – Chinese Post Comy – China – 7 June 2022 - Virtual Event
121. Coniugati anticorpo-farmaco (Antibody-Drug Conjugate, ADC) - Educazionale GITMO. Il trapianto di cellule staminali e le terapie cellulari: integrazione o alternativa terapeutica? – 24 – 25 June 2022 – Reggio Calabria, Italy
122. Le opzioni nel MM: è possibile definire una sequenza ottimale di trattamento? - L'ottimizzazione delle strategie terapeutiche per i pazienti con MM – 1 July 2022 – Alessandria, Italy
123. Fast Forward – 24 June 2022 – Bologna, Italy
124. 2nd School of Acute Leukemia – President + Chair + Speaker (Talk: Overcoming Environment-Mediated Drug Resistance in Acute Myeloid Leukemia) - 28-29 June 2022 – Rome, Italy
125. 2nd School of Multiple Myeloma – President + Chair + Speaker (Chair: CD38 IN BASIC SCIENCE AND CLINICAL PRACTICE: REFLECTING ON THE PAST TO MOVE TO THE FUTURE; Talks: Introducing anti-CD38 in daily practice of Multiple Myeloma, How I manage frontline Multiple Myeloma) - 30 June – 1 July 2022 – Rome, Italy
126. Le opzioni nel MM: è possibile definire una sequenza ottimale di trattamento? – 1 July 2022 – Alessandria, Italy
127. Meet the Expert/Professor - Current approach to Smoldering myeloma - 19th IMS Annual Meeting - August 25-27, Los Angeles
128. Workshop: Paziente giovane recidivato ad alto rischio - Stand Alone DISARMM. Destinazione Ikema - 7-8 September 2022 – Rome, Italy
129. Be the Key – 14 September – 22 November 2022 – Virtual
130. 5th International Workshop on Acute Leukemias, iwAL 2022 – 16-18 September 2022 – Nice, France
131. The new era in Multiple Myeloma - Comprehensive Cancer Care and Research Network: The IRST - AUSL Romagna Strategy to Fight Cancer – 20-21-22 September – Forli
132. Chair in Workshop IQVIA “Algoritmi terapeutici nel Mieloma Multiplo Recidivato Refrattario - Perugia - 3 October 2022
133. EHOC 2022 - How I treat relapsed/refractory multiple myeloma – Chair + Speaker - 5-8 October 2022, Istanbul, Turkey
134. La patologia plasmacellulare: update e hot topics – 7-8 October 2022, Oliena, Italy
135. Focus sulla leucemia acuta: nuove terapie ed approccio quotidiano al paziente - Nuove strategie per migliorare la fitness del microambiente nelle LAM R/R - 7-8 October, Catania, Italy
136. Unanswered Questions in Hematology – 17-19 October 2022 - Pesaro, Italy
137. 4th SOHO Italy Annual Conference – 23 – 26 October 2022 – President + Chair + Speaker (Chair: SOHO Italy – EHOG Joint Symposium - From biology to Personalized Medicine in Hematology; Clinical Care Options (CCO) –Applying Guideline Updates in AML: Global Experts Review Current Best Practice and New Therapeutic Approaches, Multiple Myeloma – Clinical Session; Talks: New frontiers in overcoming Environment-Mediated Drug Resistance in AML; EHOG-SOHO Italy State of the Art & Next Questions: Multiple Myeloma; Agile: a global, randomized, double-blind, phase 3 study of Ivosidenib + Azacitidine versus Placebo + Azacitidine in patients with newly diagnosed Acute Myeloid Leukemia with an IDH1 mutation; Clinical Care Options (CCO) –Applying Guideline Updates in AML: Global Experts Review Current Best Practice and New Therapeutic Approaches, Multiple Myeloma: State of the art in Europe,
138. High Risk AML - 11º Acute Leukemia Meeting – Speaker - 27-29 October 2022 – Madrid, Spain
139. Monoclonal antibodies: the gamechangers in Acute lymphoblastic leukema - 3rd European Conference on Controversies in Leukemias (EUROLeuk) – 2-3 November 2022 – Copenhagen, Denmark
140. Selinexor and belantamab mafodotin for the treatment of triple class refractory myeloma - Multiple Myeloma and Related Malignancies - 3-5 November 2022 – Bari, Italy
141. Mieloma Multiplo: il punto di vista del clinico - School of NGS – 4 November 2022 – Napoli, Italy
142. Expert Board of the Czech Health Research Council for Evaluation of Project Proposal – from 15 November 2022
143. Selinexor Pan-European Advisory Board Meeting – 23 Novembre 2023 – Paris, France
144. Mieloma – Terapia di prima linea per il paziente fit – Hematology the new era - 28-29 November 2022 – San Giovanni Rotondo (FG)
145. BeCL Hub – 1-19 December 2022 – Virtual Project
146. Importanza della prevenzione Herpes Zoster: focus nel paziente ematologico - La vaccinazione anti-Herpes Zoster nel paziente fragile – 3 December 2022 – Bologna, Italy
147. Carta dei diritti del paziente con Mieloma Multiplo – 6 e 16 December 2022 – Virtual Event
148. The revolution of immunotherapy in Multiple Myeloma - 9th Mayo Clinic Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk 2022 – Amelia Island, Florida - 9-11 December 2022
149. Top Dialogue GSK – 11 December 2022 – New Orleans, USA
150. Targeting new targets in myeloid malignancies - 17^th Post ASH MPN Workshop – 16 December 2022 - Virtual meeting
151. Targeting Apoptosis – 19-20 December 2022 – Bologna, Italy
152. Patient funnel Evusheld – 23 December 2023, Virtual Event
153. Current Challenges in Hematology – 25-26 January 2023 – Roma, Italy
154. Sanofi Riunione Nazionale – 12 January 2023 – Rome, Italy
155. The 7th Forum for Cellular and Humoral Immunotherapy – 26 January 2023 – Virtual meeting
156. First International “Michele Baccarani” Conference on CML and related diseases – Chair - Turin, Italy
157. Advisory Board Mieloma Multiplo Pfizer – 17 March 2023 – Rome, Italy
158. Role of NGS in Multiple Myeloma - NGS Focus Group: IgH/TCR come marcatori di Malattia Minima Residua nelle patologie Linfoproliferative – 21 March 2023 – Milan, Italy
159. Franchise Week AMGEN – 8 March 2023 – Napoli, Italy
160. Dopo la terapia di prima linea: attuali strategie terapeutiche nei pazienti ematologici – 24-25 March 2023 – Foggia, Italy
161. To treat or not to treat smoldering myeloma - 9^th World Congress on Controversies in Multiple Myeloma (COMy) – May 11-14, 2023 – Paris, France
162. CD38-targeted and other immune interventions to prevent smoldering myeloma progression - Immunotherapy in Hematological Malignancies 2023. Cuneo. 18-20 maggio 2023
163. Treatment Options for Patients With Myeloma and Renal Failure - Management of Multiple Myeloma in Special Patient Populations: No Patient Left Behind - ASCO Annual Meeting - June 2 - 6, 2023 - McCormick Place Chicago, Illinois
164. Supportive Care in Multiple Myeloma in the Era of Immunotherapy - Supportive Care of Haematological Malignancies: It is Time for Recommendation! - MASCC/JASCC/ISOO 2023 - June 22-24 2023 - Nara, Japan

Papers:

1. Cerchione C, Fabbricini R, Pane F, Luciano L.

   Vitiligo-like lesions in an adult patient treated with Imatinib Mesylate

   Leuk Res.2009 Aug; 33(8): e104-5.

2. Pane F, Quintarelli F, Esposito N, Izzo B, De Angelis B, Peluso A, Muccioli Casadei G,

   Cosenza M, Cerchione C, Camera A, Luciano L.

   Acute and Chronic Ph+ Leukemias: differential leukemogenesis pathways translate into different clinical needs

   Hematologica, Vol.94, October 2009.

3. Cerchione C, Catalano L, Cerciello G, Avilia S, Picardi M, Risitano AM, Pisano I,

   Alfinito F, Pane F.

   Role of Lenalidomide in the management of myelodysplastic syndromes with del(5q)

   associated with pure red cell aplasia (PRCA)

   Ann Hematol. 2015 Mar; 94(3): 531-4.

4. Cerchione C, Catalano L, Pareto AE, Picardi M, Pane F.

   Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience

   Support Care Cancer. 2015 Feb; 23(2): 301-2.

5. Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S.

   18-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with Multiple Myeloma: a comparative study

   Clin Nucl Med 2015 Apr; 40(4): 303-8

6. Cerchione C, Lucignano M, Pane F, Catalano L.

   Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.

   Eur J Haematol. 2016 May; 96(5): 544.

7. Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, Migliaccio I, Picardi M, Pane F.

   Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone

   Support Care Cancer. 2016 Dec; 24(12): 4835-4837.

8. Cerchione C, De Renzo A, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M.

   Pegfilgrastim in primary prophylaxis of febrile neutropenia following front-line bendamustine plus rituximab treatment in patients with indolent non Hodgkin lymphoma: a single center, real-life experience

   Support Care Cancer. 2017 Mar; 25(3): 839-845.

9. Cerchione C, Nappi D, Di Perna M, Zacheo I, Pareto AE, Picardi M, Catalano L, Pane F.

   Retreatment with Bendamustine-Bortezomib-Dexamethasone in a patient with relapsed/refractory multiple myeloma

   Case Rep Hematol. 2016; 2016: 6745286.

10. Cerchione C, Cerciello G, Avilia S, Della Pepa R, Pugliese N, Picardi M, Pane F, Catalano L.

    Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease

    Blood Transfus. 2016 Oct 24; 1-4.

11. Della Pepa R, Pagano L, Cerchione C, Pugliese N, Pane F, Picardi M.

    Reply to the letter to the editor "chronic disseminated candidiasis" by Kenneth Rolston

    Support Care Cancer. 2017 Apr; 25(4): 1045-1046.

12. Pugliese N, Di Perna M, Cozzolino I, Ciancia G, Pettinato G, Zeppa P, Varone V, Masone S, Cerchione C, Della Pepa R, Simeone L, Salvatore C, Pane F, Picardi M.

    Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma

    Ann Hematol. 2017 Apr; 96(4): 627-637.

13. Cerchione C, Peluso I, Nappi D, Pareto AE, Picardi M, Martinelli V, Pane F.

    Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

    Ann Hematol. 2017 Apr; 96(4): 697-699.

14. Cerchione C, Nappi D, Di Perna M, Zacheo I, Migliaccio I, Salvatore D, Picardi M, Pane F, Catalano L.

    A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide

    Clinical Case reports, Vol 5, Issue 4, April 2017 Pages 505-507.

15. Cerchione C, Maraolo AE, Marano L, Pugliese N, Nappi D, Tosone G, Cimmino I, Cozzolino I, Martinelli V, Pane F, Picardi M.

    Secondary syphilis mimicking malignancy: A case report and review of literature

    J Infect Chemother. 2017 Aug; 23(8): 576-578.

16. Pugliese N, Salvatore P, Iula VD, Catania MR, Chiurazzi F, Della Pepa R, Cerchione C, Raimondo M, Giordano C, Simeone L, Caruso S, Pane F, Picardi M.

    Ultrasonography-driven tigecycline-based antibiotic therapy significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia

    Cancer Med. 2017. Jul; 6(7): 1500-1511.

17. Fiore M, Maraolo AE, Chiodini P, Cerchione C, Gentile I, Borgia G, Pace MC.

    Is anticoagulation with novel oral anticoagulants an effective treatment for tubercolosis patients not achieving a therapeutic range with vitamin k antagonists? A Systematic Review.

    Cardiovasc Hematol Disord Drug Targets. 2017; 17(2): 105-110.

18. Della Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, Cerchione C, Raimondo M, Di Perna M, Troncone G, Ciancia G, Intrieri M, Pane F.

    Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lyphocyte-predominant Hodgkin lymphoma

    Br J Haematol. 2017 Jul 24.

19. Mondello P, Steiner N, WIllenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M.

    Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

    Oncologist. 2018 Jan 9.

20. Romano A, Laura Parrinello N, Cerchione C, Letizia Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Alberto Palumbo G.

    The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.

    Blood Cancer J. 2017 Dec 15; 7(12): 649.

21. Romano A, Cerchione C, Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Palumbo G

    The neutrophil-lymphocyte ratio (NLR) and the lymphocyte-monocyte ratio (LMR) predict progression free survival in patients with newly diagnosed multiple myeloma treated upfront with novel agents

    Blood Cancer J. 2017 Dec 15; 7(12): 649.

22. Cerchione C, Nappi D, Pareto AE, Romano A, Picardi M, Pane F, Catalano L

    Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience

    Anticancer Drugs. 2018 Feb 7.

23. Della Pepa R, Cerchione C, Pugliese N, Colicchio R, Salvatore P, Sirignano C, Soscia E, Pagano L, Sanguinetti M, Pane F, Picardi M.

    Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary osbservations on role of 1,3-beta-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography

    Support Care Cancer. 2018 Mar 9.

24. Cerchione C, Nappi D, Pareto AE, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L

    Safety and comfort of domestic bortezomib injection in real life experience

    Support Care Cancer 2018 Mar 24.

25. Cerchione C, De Renzo A, Nappi D, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M.

    Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.

    Support Care Cancer 2019 Jan 23.

26. Picardi M, Della Pepa R, Cerchione C, Pugliese N, Mortaruolo C, Trastulli F, Giordano C, Grimaldi F, Zacheo I, Raimondo M, Chiurazzi F, Pane F.

    A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison.

    Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):e184-e194. doi: 10.1016/j.clml.2018.12.008. Epub 2018 Dec 20.

27. Pugliese N, Giordano C, Nappi D, Luciano L, Cerchione C, Annunziata M, Casale B, Crisà E, Villa MR, Pezzullo L, Iovine M, Picardi M, Grimaldi F, Pane F, Martinelli V.

    Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

    Cancer Med. 2019 Jun;8(6):2802-2809. doi: 10.1002/cam4.2147. Epub 2019 Apr 17.

28. Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U.

    CAR-T cell therapy: a potential new strategy against prostate cancer.

    J Immunother Cancer. 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7. Review.

29. Cerchione C, Martinelli G, Pedatella S, De Nisco M, Pugliese N, Manfra M, Marra N, Ronconi S, De Giorgi U, Altini M, Simonetti G, Di Rorà AGL, Bravaccini S, Catalano L, Dora Iula V, Pagano F, Picardi M, Bolognese A, Pane F, Martinelli V.

    An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia.

    Anticancer Drugs. 2020 Jan;31(1):67-72. doi: 10.1097/CAD.0000000000000850;

30. Claudio Cerchione, Giovanni Martinelli, Marco Picardi, Novella Pugliese, Davide Nappi, Aniello Casoria, Angela Gravetti, Delia Cangini, Maria Benedetta Giannini, Sonia Ronconi, Giorgia Simonetti, Andrea Ghelli Luserna Di Rorà, Ugo De Giorgi, Mattia Altini, Sara Bravaccini, Ilaria Santoriello, Cristiano Minucci, Fabrizio Pane and Vincenzo Martinelli.

    Combined oral fentanyl citrate and midazolam as premedication for bone marrow aspiration and biopsy in patients with hematological malignancies: a randomized, controlled and patient-blinded clinical trial

    J Clin Med. 2020 Feb 1;9(2):395. doi: 10.3390/jcm9020395.

31. Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F.

    Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica. 2020 Feb 27:haematol.2019.241513. doi: 10.3324/haematol.2019.241513. Online ahead of print.

32. Mondello P, Musolino C, Dogliotti I, Bohn JP, Cavallo F, Ferrero S, Botto B, Cerchione C, Nappi D, De Lorenzo S, Martinelli G, Wolf D, Schmitt C, Loseto G, Cuzzocrea S, Willenbacher W, Mian M, Straus DJ

    ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.

    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25871. Online ahead of print.

33. Lucchesi A, Silimbani P, Musuraca G, Cerchione C, Martinelli G, Di Carlo P, Napolitano M.

    Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.

    J Med Virol. 2020 Jun 24:10.1002/jmv.26217. doi: 10.1002/jmv.26217. Online ahead of print.

34. Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F.

    KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.

    Ann Hematol. 2020 Jun 25. doi: 10.1007/s00277-020-04158-4. Online ahead of print.

35. Nolan S, Vignali M, Klinger M, Dines JN, Kaplan IM, Svejnoha E, Craft T, Boland K, Pesesky M, Gittelman RM, Snyder TM, Gooley CJ, Semprini S, Cerchione C, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Sambri V, Martinelli G, Goldman JD, Heath JR, Notarangelo LD, Carlson JM, Martinez-Lopez J, Robins HS.

    A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2.

    Res Sq. 2020 Aug 4:rs.3.rs-51964. doi: 10.21203/rs.3.rs-51964/v1. Preprint.

36. Snyder TM, Gittelman RM, Klinger M, May DH, Osborne EJ, Taniguchi R, Zahid HJ, Kaplan IM, Dines JN, Noakes MN, Pandya R, Chen X, Elasady S, Svejnoha E, Ebert P, Pesesky MW, De Almeida P, O'Donnell H, DeGottardi Q, Keitany G, Lu J, Vong A, Elyanow R, Fields P, Greissl J, Baldo L, Semprini S, Cerchione C, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Imberti L, Sottini A, Quiros-Roldan E, Rossi C, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Tompkins MF, Alba C, Dalgard C, Sambri V, Martinelli G, Goldman JD, Heath JR, Su HC, Notarangelo LD, Martinez-Lopez J, Carlson JM, Robins HS.

    Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels.

    medRxiv. 2020 Aug 4:2020.07.31.20165647. doi: 10.1101/2020.07.31.20165647. Preprint.

37. Cerchione C, Nappi D, Musuraca G, Lucchesi A, Cimmino I, Pane F, De Renzo A, Martinelli G.

    Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.

    Medicine (Baltimore). 2020 Aug 14;99(33):e21440. doi: 10.1097/MD.0000000000021440.

38. Bravaccini S, Martinelli G, Cerchione C.

    What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?

    Cell Transplant. 2020 Jan-Dec;29:963689720950209. doi: 10.1177/0963689720950209.

39. Ricciuti G, Falcone AP, Cascavilla N, Martinelli G, Cerchione C.

    Autologous stem cell transplantation in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04114-2. Online ahead of print.

40. Nagarajan C, Tan MS, Chen Y, Martinelli G, Cerchione C.

    Current and future perspectives of maintenance therapy in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04117-8. Online ahead of print.

41. Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C.

    BCMA-targeting approaches for treatment of multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04121-X. Online ahead of print.

42. Derudas D, Capraro F, Martinelli G, Cerchione C.

    Old and new generation immunomodulatory drugs in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04125-7. Online ahead of print.

43. Santoro M, Romano A, Mancuso S, Siragusa S, Di Raimondo F, Martinelli G, Cerchione C.

    Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04133-6. Online ahead of print.

44. Romano A, Santoro M, Conticello C, Siragusa S, Di Raimondo F, Martinelli G, Cerchione C.

    Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04141-5. Online ahead of print.

45. Martino M, Paviglianiti A, Gentile M, Martinelli G, Cerchione C.

    Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04142-7. Online ahead of print.

46. Gentile M, Morabito F, Martino M, Vigna E, Martino EA, Mendicino F, Martinelli G, Cerchione C.

    Chemotherapy-based regimens in multiple myeloma in 2020.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04145-2. Online ahead of print.

47. Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, Martín-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, Cerchione C.

    CAR T cells targeting options in the fight against multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04146-4. Online ahead of print.

48. Vozella F, Fazio F, Lapietra G, Petrucci MT, Martinelli G, Cerchione C.

    Monoclonal antibodies in multiple myeloma.

    Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04149-X. Online ahead of print.

49. Mosquera Orgueira A, Bao Pérez L, Mosquera Torre A, Peleteiro Raíndo A, Cid López M, Diaz Arias JA, Ferreiro Ferro R, Antelo Rodriguez B, González Pérez MS, Albors Ferreiro M, Alonso Vence N, Pérez Encinas MM, Bello López JL, Martinelli G, Cerchione C.

    FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.06989-X. Online ahead of print.

50. Abdul-Hamil NA, Wong GC, Nagarajan C, Martinelli G, Cerchione C.

    Midostaurin in acute myeloid leukemia: review of current evidence and practical considerations in routine clinical use.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07014-7. Online ahead of print.

51. Palmieri R, Buccisano F, Maurillo L, Del Principe MI, Paterno G, Venditti A, Martinelli G, Cerchione C.

    Current strategies for detection and approach to easurable residual disease in Acute Myeloid Leukemia.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07016-0. Online ahead of print.

52. Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorá A, Simonetti G, Martinelli G, Cerchione C.

    CPX-351 - Daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07017-2. Online ahead of print.

53. Cangini D, Silimbani P, Cafaro A, Giannini MB, Masini C, Ghelli Luserna Di Rorá A, Simonetti G, Martinelli G, Cerchione C.

    Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07018-4. Online ahead of print.

54. Gottardi M, Sperotto A, Ghelli Luserna Di Rorá A, Padella A, Cangini D, Giannini MB, Simonetti G, Martinelli G, Cerchione C.

    Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and feature.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07019-6. Online ahead of print.

55. Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, Cerchione C.

    Enasidenib and Ivosidenib in AML.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07024-X. Online ahead of print.

56. Lanza F, Maffini E, Saraceni F, Massari E, Rondoni M, Daghia G, Olivieri A, Cerchione C amd Martinelli G.

    New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.

    Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07031-7. Online ahead of print.

57. Cerchione C, Martinelli G.

    Acute leukemias in 2020: state of the art.

    Minerva Med. 2020 Sep 22. doi: 10.23736/S0026-4806.20.07049-4. Online ahead of print.

58. Montefusco V, Mussetti A, Sala MR, Martinelli G, Cerchione C.

    Old and new generation proteasome inhibitors in multiple myeloma.

    Panminerva Med. 2020 Sep 22. doi: 10.23736/S0031-0808.20.04148-8. Online ahead of print.

59. Cerchione C, Martinelli G.

    Multiple myeloma in 2020: state of the art.

    Panminerva Med. 2020 Sep 22. doi: 10.23736/S0031-0808.20.04159-2. Online ahead of print.

60. Ghelli Luserna di Rorà A, Cerchione C, Martinelli G, Simonetti G.

    A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.

    J Hematol Oncol. 2020 Sep 21;13(1):126. doi: 10.1186/s13045-020-00959-2.

61. Molica M, Noguera NI, Trawinska MM, Martinelli G, Cerchione C and Abruzzese E.

    Treatment free remission in chronic myeloid leukemia: Lights and shadows.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8950. doi: 10.4081/hr.2020.8950. eCollection 2020 Sep 21.

62. Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F.

    How we manage smoldering multiple myeloma.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8951. doi: 10.4081/hr.2020.8951. eCollection 2020 Sep 21.

63. Montefusco V, Martinelli G, Cerchione C.

    How I manage frontline transplant-eligible multiple myeloma in Italy.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8954. doi: 10.4081/hr.2020.8954. eCollection 2020 Sep 21.

64. Lee HC, Cerchione C.

    How I treat relapsed and/or refractory multiple myeloma.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8955. doi: 10.4081/hr.2020.8955. eCollection 2020 Sep 21.

65. Derudas D, Capraro F, Martinelli G, Cerchione C.

    How I manage frontline transplant-ineligible multiple myeloma.

    Hematol Rep. 2020 Sep 21;12(Suppl 1):8956. doi: 10.4081/hr.2020.8956. eCollection 2020 Sep 21.

66. Ravaioli S, Tebaldi M, Fonzi E, Angeli D, Mazza M, Nicolini F, Lucchesi A, Fanini F, Pirini F, Tumedei MM, Cerchione C, Viale P, Sambri V, Martinelli G, Bravaccini S.

    ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients.

    Cell Transplant. 2020 Jan-Dec;29:963689720968749. doi: 10.1177/0963689720968749.

67. Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C,

    Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art

    Front. Oncol. | doi: 10.3389/fonc.2020.592487

68. Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, Cerchione C, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O

    Hydroxychloroquine as prophylaxis for COVID-19: a review

    Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020.

69. Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, Cerchione C.

    Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.

    Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.

70. Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C.

    A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.

    Int J Mol Sci. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150.

71. Cimmino I, Bravaccini S, Cerchione C.

    Urinary Biomarkers in Tumors: An Overview.

    Methods Mol Biol. 2021;2292:3-15. doi: 10.1007/978-1-0716-1354-2_1.

72. Kaufman GP, Cerchione C.

    Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.

    Front Oncol. 2021 Feb 3;10:624573. doi: 10.3389/fonc.2020.624573. eCollection 2020.

73. Matteucci F, Paganelli G, Martinelli G, Cerchione C.

    PET/CT in Multiple Myeloma: Beyond FDG.

    Front Oncol. 2021 Jan 25;10:622501. doi: 10.3389/fonc.2020.622501. eCollection 2020.

74. Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, Cerchione C, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, Bello López JL.

    Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

    PLoS One. 2021 Feb 16;16(2):e0247093. doi: 10.1371/journal.pone.0247093. eCollection 2021.

75. Bolli N, Martinelli G, Cerchione C.

    The molecular pathogenesis of multiple myeloma.

    Hematol Rep. 2020 Dec 18;12(3):9054. doi: 10.4081/hr.2020.9054. eCollection 2020 Dec 2.

    PMID: 33408844 Free PMC article.

76. Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F.

    Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.

    Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.

77. Rossi A, Prochowski Iamurri A, Cerchione C, Gentili N, Danesi V, Altini M, Paganelli G, Barone D.

    Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic.

    Insights Imaging. 2020 Dec 3;11(1):129. doi: 10.1186/s13244-020-00935-x.

78. Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C.

    Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

    Front Oncol. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. eCollection 2020.

79. Picardi M, Giordano C, Della Pepa R, Cerchione C, Pugliese N, Leone A, Vitiello S, Pane F.

    Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma.

    Eur J Haematol. 2020; 105: 667-671".

    Eur J Haematol. 2020 Nov 30. doi: 10.1111/ejh.13558. Online ahead of print.

80. Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C.

    Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

    Front Oncol. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. eCollection 2020.

81. Rossi A, Prochowski Iamurri A, Cerchione C, Gentili N, Danesi V, Altini M, Paganelli G, Barone D.

    Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic.

    Insights Imaging. 2020 Dec 3;11(1):129. doi: 10.1186/s13244-020-00935-x.

    PMID: 33270166 Free PMC article. Review.

82. Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F.

    Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.

    Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.

83. Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, Cerchione C, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O.

    Hydroxychloroquine as Prophylaxis for COVID-19: A Review.

    Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020.

84. Bolli N, Martinelli G, Cerchione C.

    The molecular pathogenesis of multiple myeloma.

    Hematol Rep. 2020 Dec 18;12(3):9054. doi: 10.4081/hr.2020.9054. eCollection 2020 Dec 2.

85. Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, Cerchione C, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, Bello López JL.

    Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

    PLoS One. 2021 Feb 16;16(2):e0247093. doi: 10.1371/journal.pone.0247093. eCollection 2021.

    PMID: 33592069 Free PMC article.

86. Matteucci F, Paganelli G, Martinelli G, Cerchione C.

    PET/CT in Multiple Myeloma: Beyond FDG.

    Front Oncol. 2021 Jan 25;10:622501. doi: 10.3389/fonc.2020.622501. eCollection 2020.

87. Kaufman GP, Cerchione C.

    Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.

    Front Oncol. 2021 Feb 3;10:624573. doi: 10.3389/fonc.2020.624573. eCollection 2020.

    PMID: 33614504 Free PMC article. Review.

88. Cimmino I, Bravaccini S, Cerchione C.

    Urinary Biomarkers in Tumors: An Overview.

    Methods Mol Biol. 2021;2292:3-15. doi: 10.1007/978-1-0716-1354-2_1.

89. Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C.

    A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.

    Int J Mol Sci. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150.

    PMID: 33670075 Free PMC article. Review.

90. Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, Cerchione C.

    Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.

    Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.

91. Cerchione C, Locatelli F, Martinelli G.

    Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    Front Oncol. 2021 Mar 25;11:632231. doi: 10.3389/fonc.2021.632231. eCollection 2021.

    PMID: 33842339 Free PMC article. Review.

92. Marconi G, Giannini MB, Bagnato G, Simonetti G, Cerchione C, Mosquera Orgueira A, Musuraca G, Martinelli G.

    The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.

    Expert Opin Drug Saf. 2021 Apr 14:1-9. doi: 10.1080/14740338.2021.1913120.

93. Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Díaz Arias JÁ, González Pérez MS, Antelo Rodríguez B, Alonso Vence N, Bao Pérez L, Ferreiro Ferro R, Albors Ferreiro M, Abuín Blanco A, Fontanes Trabazo E, Cerchione C, Martinnelli G, Montesinos Fernández P, Mateo Pérez Encinas M, Luis Bello López J.

    Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling.

    Front Oncol. 2021 Mar 29;11:657191. doi: 10.3389/fonc.2021.657191. eCollection 2021.

94. Cerchione C, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H.

    IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.

    Front Oncol. 2021 Mar 29;11:639387. doi: 10.3389/fonc.2021.639387. eCollection 2021.

95. Picardi M, Cavaliere C, Della Pepa R, Nicolai E, Soricelli A, Giordano C, Pugliese N, Rascato MG, Cappuccio I, Campagna G, Cerchione C, Vigliar E, Troncone G, Mascolo M, Franzese M, Castaldo R, Salvatore M, Pane F

    PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.

    Ann Hematol. 2021 Jun;100(6):1525-1535. doi: 10.1007/s00277-021-04537-5. Epub 2021 Apr 28.

96. Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F, Gentile M.

    Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.

    Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021.

97. Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

    Cerchione C, Nappi D, Martinelli G.

    Support Care Cancer. 2021 May 14. doi: 10.1007/s00520-021-06266-x. Online ahead of print.

    PMID: 33990881 Review.

98. Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A.

    Immunotherapy in Acute Myeloid Leukemia: Where We Stand.

    Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021.

    PMID: 34041025 Free PMC article. Review.

99. Martino M, Canale FA, Alati C, Vincelli ID, Moscato T, Porto G, Loteta B, Naso V, Mazza M, Nicolini F, Ghelli Luserna di Rorà A, Simonetti G, Ronconi S, Ceccolini M, Musuraca G, Martinelli G, Cerchione C.

    CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

    Cancers (Basel). 2021 May 27;13(11):2639. doi: 10.3390/cancers13112639.

    PMID: 34072068 Free PMC article. Review.

100. Simonetti G, Angeli D, Petracci E, Fonzi E, Vedovato S, Sperotto A, Padella A, Ghetti M, Ferrari A, Robustelli V, Di Liddo R, Conconi MT, Papayannidis C, Cerchione C, Rondoni M, Astolfi A, Ottaviani E, Martinelli G, Gottardi M.

     Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia.

     Front Oncol. 2021 Jun 2;11:684396. doi: 10.3389/fonc.2021.684396. eCollection 2021.

     PMID: 34150648 Free PMC article.

101. Cerchione C, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao Pérez L, Marconi G, Isidori A, Pérez Encinas MM, Martinelli G.

     Safety of FLT3 inhibitors in patients with acute myeloid leukemia.

     Expert Rev Hematol. 2021 Sep;14(9):851-865. doi: 10.1080/17474086.2021.1969911. Epub 2021 Aug 30.

     PMID: 34424108

102. Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G.

     Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

     Cell Biol Toxicol. 2021 Sep 14. doi: 10.1007/s10565-021-09640-x. Online ahead of print. PMID: 34519926

103. Gottardi M, Simonetti G, Sperotto A, Nappi D, Ghelli Luserna di Rorà A, Padella A, Norata M, Giannini MB, Musuraca G, Lanza F, Cerchione C, Martinelli G.

     Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.

     Cancers (Basel). 2021 Sep 11;13(18):4566. doi: 10.3390/cancers13184566. PMID: 34572794 Free article. Review.

104. Martino M, Pitino A, Gori M, Bruno B, Crescimanno A, Federico V, Picardi A, Tringali S, Ingrosso C, Carluccio P, Pastore D, Musuraca G, Paviglianiti A, Vacca A, Serio B, Storti G, Mordini N, Leotta S, Cimminiello M, Prezioso L, Loteta B, Ferreri A, Colasante F, Merla E, Giaccone L, Busca A, Musso M, Scalone R, Di Renzo N, Marotta S, Mazza P, Musto P, Attolico I, Selleri C, Canale FA, Pugliese M, Tripepi G, Porto G, Martinelli G, Carella AM Jr, Cerchione C

     Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. Front Oncol. 2021 Sep 6;11:740079. doi: 10.3389/fonc.2021.740079. eCollection 2021.PMID: 34616684

105. Pallotti MC, Rossi R, Scarpi E, Dall'Agata M, Ricci M, Ceccolini M, Ronconi S, Valenti V, Maltoni M, Martinelli G, Cerchione C.

     Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes.

     Support Care Cancer. 2022 Mar;30(3):2293-2298. doi: 10.1007/s00520-021-06560-8. Epub 2021 Oct 31. PMID: 34718886

106. Maltoni R, Ravaioli S, Bronte G, Mazza M, Cerchione C, Massa I, Balzi W, Cortesi M, Zanoni M, Bravaccini S.

     Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?

     Transl Oncol. 2022 Jan;15(1):101300. doi: 10.1016/j.tranon.2021.101300. Epub 2021 Dec 1. PMID: 34864401

107. Mosquera Orgueira A, Cid López M, Peleteiro Raíndo A, Abuín Blanco A, Díaz Arias JÁ, González Pérez MS, Antelo Rodríguez B, Bao Pérez L, Ferreiro Ferro R, Aliste Santos C, Pérez Encinas MM, Fraga Rodríguez MF, Cerchione C, Mozas P, Bello López JL.

     Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models.

     Front Oncol. 2022 Jan 10;11:705010. doi: 10.3389/fonc.2021.705010. eCollection 2021. PMID: 35083135

108. Cerchione C, Usmani SZ, Stewart AK, Kaiser M, Rasche L, Kortüm M, Mateos MV, Spencer A, Sonneveld P, Anderson KC.

     Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment

     Front Oncol. 2022 Feb 8;12:820768. doi: 10.3389/fonc.2022.820768. eCollection 2022.cPMID: 35211412

109. Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, Del Fabro V, Leotta S, Markovic U, Motta G, Parisi M, Stagno F, Palumbo GA, Di Raimondo F.

     Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.

     Cancers (Basel). 2022 Feb 24;14(5):1173. doi: 10.3390/cancers14051173. PMID: 35267478

110. Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M.

     Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.

     Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. PMID: 35608183

111. Messina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, Fracchiolla NS, Forghieri F, Candoni A, Mengarelli A, Martelli MP, Venditti A, Carella AM, Albano F, Mancini V, Massimo B, Arena V, Sargentini V, Sciumè M, Pastore D, Todisco E, Roti G, Siragusa S, Ladetto M, Pravato S, De Bellis E, Simonetti G, Marconi G, Cerchione C, Fazi P, Vignetti M, Amadori S, Martinelli G, Voso MT.

     Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol.

     Cancers (Basel). 2022 Jun 18;14(12):3012. doi: 10.3390/cancers14123012. PMID: 35740677

112. Botta C, Gigliotta E, Paiva B, Anselmo R, Santoro M, Otero PR, Carlisi M, Conticello C, Romano A, Solimando AG, Cerchione C, Vià MD, Bolli N, Correale P, Di Raimondo F, Gentile M, San Miguel J, Siragusa S.

     Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.

     Hematol Oncol. 2022 Dec;40(5):987-998. doi: 10.1002/hon.3041. Epub 2022 Jul 11. PMID: 35794705

113. Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, Navarro EA, Pasetto A, Nascimento Silva D, Ancarani V, Sambri V, Calabrò L, Martinelli G, Mazza M.

     T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer.

     Int J Mol Sci. 2022 Aug 2;23(15):8590. doi: 10.3390/ijms23158590. PMID: 35955721

114. Pascale SP, Nuccorini R, Pierri T, Di Mare R, Fabio L, Lerose E, Merlino MA, Schiavo P, Amendola A, Brucoli G, Caputo MD, Chitarrelli I, Cimminiello M, Coluzzi S, Filardi NB, Matturro A, Vertone D, Poggiaspalla M, Malaspina F, Musuraca G, Coralluzzo G, Mannarella C, Musto C, Bellettieri AP, Martinelli G, Cerchione C, Pizzuti M.

     Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.

     Front Immunol. 2022 Aug 8;13:892331. doi: 10.3389/fimmu.2022.892331. eCollection 2022. PMID: 36003404

115. Mosquera Orgueira A, Peleteiro Raíndo A, Díaz Arias JÁ, Antelo Rodríguez B, López Riñón M, Cerchione C, de la Fuente Burguera A, González Pérez MS, Martinelli G, Montesinos Fernández P, Pérez Encinas MM.

     Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

     Front Oncol. 2022 Aug 17;12:968340. doi: 10.3389/fonc.2022.968340. eCollection 2022. PMID: 36059646

116. Cerchione C, Nappi D, Romano A, Martinelli G.

     Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.

     Cancers (Basel). 2022 Aug 23;14(17):4063. doi: 10.3390/cancers14174063. PMID: 36077600

117. Bravaccini S, Nicolini F, Zanoni M, Gaimari A, Cerchione C, Maltoni R, Pirini F, Mazzotti L, Cortesi M, Ravaioli S, Tumedei MM, Mazza M.

     Why the complications of COVID-19 patients differ in elderly and young cancer patients.

     Transl Oncol. 2022 Dec;26:101541. doi: 10.1016/j.tranon.2022.101541. Epub 2022 Sep 12. PMID: 36119944

118. Guolo F, Cerchione C, Vernarecci C, Isidori A.

     Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

     Front Oncol. 2022 Sep 9;12:1020185. doi: 10.3389/fonc.2022.1020185. eCollection 2022. PMID: 36158678

119. Wilde L, Binder A, Cerchione C, Isidori A.

     Editorial: COVID-19 and hematological malignancies: Volume II.

     Front Oncol. 2022 Oct 10;12:1044582. doi: 10.3389/fonc.2022.1044582. eCollection 2022. PMID: 36300086

120. Martino M, Naso V, Loteta B, Canale FA, Pugliese M, Alati C, Musuraca G, Nappi D, Gaimari A, Nicolini F, Mazza M, Bravaccini S, Derudas D, Martinelli G, Cerchione C.

     Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon.

     Int J Mol Sci. 2022 Nov 1;23(21):13332. doi: 10.3390/ijms232113332. PMID: 36362130

121. Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G; AVALON Cooperative Group.

AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.

Cancer. 2023 Jan 24. doi: 10.1002/cncr.34608. Online ahead of print. PMID: 36692409

Abstracts/Poster presentations in national/international events:

1. Luciano L, Cerchione C, Becchimanzi C, Pane F, Rotoli B.

   “Imatinib Mesylate and Cardiac function”

   Haematologica Abstract Book, SIE, Vol. 92 supplement no.3, October 2007

2. V. Schiano Lomoriello, R. Esposito, R.Viceconti, C.Cerchione, L.Luciano, M.Galderisi

   “L'Imatinib aumenta la massa ventricolare ed il diametro atriale sinistro nei pazienti affetti da leucemia mieloide cronica”

   Giornale Italiano di Cardiologia volume 9, Suppl.2 al n.5 May 2008

3. Olim P, Sousa P, Carda J, Sousa M.I., Tavares P, Cerchione C

   “Linfoma osseo primario – a experiencia de uma instituicao”

   Abstract Congresso Nazionale Società Portoghese di Ematologia September 2008

4. Luciano L, Cerchione C, Schiano Lomoriello V, Esposito R, Fabbricini R, Galderisi M, Pane F, Rotoli B

   “Effect of Imatinib Mesylate on cardiac function”

   Haematologica Abstract Book, SIES, Vol. 93 supplement no.2, September 2008

5. Caliendo I, Luciano L, Danise P, Rivellini F, De Vita B, Guerriero A, Cerchione C, Tafuri A, Clemente L, Ingenito M, D'Arco A

   “Progression of a myelodysplastic syndrome, with nonrandom aneuploidy of chromosome 21, to acute myeloid leukemia with t(9;15) (q22;q22) as the sole cytogenetic abnormality”

   Haematologica Abstract Book, SIES, Vol. 93 supplement no.2, September 2008

6. Luciano L, Cerchione C, Ciancia R, Pane F

   “Renal failure associated to tyrosine kinase inhibitors”

   Haematologica Abstract Book, EHA, Vol. 95 supplement no.2, June 2010

7. Luciano L, Cerchione C, Ciancia R, Pane F

   “Successful pregnancies in Chronic Myeloid Leukaemia male patient on Imatinib therapy”

   Haematologica Abstract Book, EHA, Vol. 95 supplement no.2, June 2010

8. Cerchione C, Luciano L, Ciancia R, Pane F

   “Renal failure associated to tyrosine kinase inhibitors”

   Abstract Book Riunione Annuale dei Centri di Ematologia Meridionale ed Insulare (SIE SUD), con Comunicazione Orale

9. Cerchione C, Luciano L, Ciancia R, Pane F

   “Successful pregnancies in Chronic Myeloid Leukaemia male patient on Imatinib therapy”

   Abstract Book Riunione Annuale dei Centri di Ematologia Meridionale ed Insulare (SIE SUD), con Comunicazione Orale

10. Cerchione C, Luciano L, Ciancia R, Pane F

    “LA PATERNITA’ NEI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN TERAPIA CON GLI INIBITORI DELLE TIROSINCHINASI”

    Abstract Book Giornate Scientifiche “Bruno Rotoli” Federico II

11. Cerchione C, Luciano L, Ciancia R, Pane F

    “NEFROTOSSICITA' NEI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN TERAPIA CON GLI INIBITORI DELLE TIROSINCHINASI”

    Abstract Book Giornate Scientifiche “Bruno Rotoli” Federico II

12. Della Pepa R., Cacciapuoti V., Cerciello G., Avilia S., Cerchione C., Luciano L., Alfinito F., Pane F.

    “La tecnica FISH (Fluorescent In Situ Hybridization) è un ottimo strumento per migliorare la diagnosi delle Sindromi Mielodisplastiche Primarie (MDS)”

    Abstract Book Giornate Scientifiche “Bruno Rotoli” Federico II

13. Cerchione C, Cerciello G, Della Pepa R, Ciancia R, Matarazzo M, Alfinito F, Pane F

    “Combination of deferasirox and deferoxamine for management of iron overload in myelodysplastic syndromes in hepatopathic patient: A case report”

    Leukemia Research, Volume 35, Supplement 1, S1-S166 (May 2011)

14. Cerciello G, Cerchione C, Cosenza M, Luciano L, Alfinito F, Pane F, Risitano AM

    “Myelodysplastic syndromes and pure red cell aplasia with del (5q)”

    Leukemia Research, Volume 35, Supplement 1, S1-S166 (May 2011)

15. Cerchione C, Cerciello G, Della Pepa R, Ciancia R, Matarazzo M, Alfinito F, Pane F

    “Safety and efficacy of combination therapy with Deferasirox and Deferoxamine for management of iron overload in multitransfused hepatopatic patient with myelodysplastic syndrome: a case report”

    Haematologica Abstract Book, EHA London, Vol. 96 supplement no.2, June 2011

16. Della Pepa R, Cerchione C, Cerciello G, Izzo B, Muccioli Casadei G, Alfinito F, Pane F

    “Myelodysplastic syndromes with del(5q) and JAK2 V617F mutation: a case of hematologic response to Lenalidomide therapy”

    Haematologica Abstract Book, EHA London, Vol. 96 supplement no.2, June 2011

17. Pugliese N, Gravetti A, Quintarelli C, Madonna E, Izzo B, Muccioli Casadei G, Cerchione C, Martinelli V, Pane F

    “Hydroxyurea plus Anagrelide combined therapy is more suitable than sequence schedule of the two drugs”

    Haematologica Abstract Book, EHA London, Vol. 96 supplement no.2, June 2011

18. Ciancia R, Cerchione C, Seneca E, Beneduce G, Pisano I, Cacciapuoti V, Luciano L, Pane F

    “Myelodysplastic/myeloproliferative neoplasm: a future therapeutic perspective”

    Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011

19. Cerchione C, Cerciello G, Della Pepa R, Avilia S, Ciancia R, Matarazzo M, Alfinito F, Pane F

    “Management of iron overload in myelodysplastic syndromes (MDS): combination of deferasirox and deferoxamine in a hepatopatic patient”

    Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011

20. Cerciello G, Cerchione C, Della Pepa R, Avilia S, Cosenza M, Luciano L, Alfinito F, Pane F, Risitano AM

    “Pure red cell aplasia (PRCA) and myelodysplastic syndromes (MDS) with del (5q)”

    Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011

21. Della Pepa R, Cerchione C, Cerciello G, Avilia S, Izzo B, Muccioli Casadei G, Alfinito F, Pane F

    “Hematologic response to Lenalidomide in JAK2 V617F-positive essential thrombocytemia (TE) associated to del (5q) myelodysplastic syndrome: a case report”

    Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011

22. Luciano L, Seneca E, Cerchione C, Ciancia R, Pisano I, Cosenza M, Peluso AL, Pane F

    “A particular mutational status in a chronic myeloid leukemia patient treated with different tyrosin-kinase inhibitors”

    Haematologica Abstract Book, SIE Napoli, Vol. 96 supplement no.3, October 2011

23. Pugliese N, Marano L, Gherghi M, Quintarelli C, De Angelis B, Cerchione C, Errichiello S, Muccioli Casadei G, Beneduce G, Martinelli V, Pane F

    “Anagrelide in monotherapy or combined with hydroxyurea yields a high rate of complete response in Essential Thrombocythemia”

    Haematologica Abstract Book, EHA Amsterdam, Vol.97 supplement no.1, June 2012

24. Pugliese N, Marano L, Picardi M, Gherghi M, Ciancia G, Cerchione C, Quintarelli C, Martinelli V, Pane F

    “Spleen is the hidden hitch of Essential Thrombocythemia”

    Haematologica Abstract Book, EHA Amsterdam, Vol.97 supplement no.1, June 2012

25. Cerchione C, Cerciello G, Della Pepa R, Matarazzo M, Alfinito F, Pane F

    “Deferasirox and Deferoxamine combination therapy: a case of management of iron overload in Myelodysplastic Syndrome in an hepatopathic patient”

    Haematologica Abstract Book, EHA Amsterdam, Vol.97 supplement no.1, June 2012

26. Cerchione C, Battipaglia G, Migliaccio I, Salvatore S, Camera A, Cerciello G, Della Pepa R, Chiurazzi F, Pane F

    “Secondary hemophagocytic lymphohistiocytosis five years after acute myeloid leukemia: a case report”

    Haematologica Abstract Book, Sies Roma, Vol.97 supplement no.2, October 2012

27. Claudio Cerchione, Fabrizio Pane, Marco Picardi

    “Monitoraggio dei livelli plasmatici degli antimicotici azolici nei pazienti neutropenici e correlazioni con efficacia terapeutica ed effetti tossici”

    Presentazione al Progetto Under40 in Hematology, Napoli 2012

28. C. Cerchione, V. Russo, F. Tucci, G. Loffredo, N. Marra, R. Parasole, F. Petruzziello, N. Crescenzio, G. Menna, V. Poggi

    “La sindrome autoimmune linfoproliferativa (ALPS): Esperienza del nostro centro AIEOP”

    Librone abstract XXXVIII Congresso nazionale AIEOP, Roma, Giugno 2013

29. C. Cerchione, V. Russo, F. Tucci, G. Loffredo, N. Marra, R. Parasole, F. Petruzziello, V. Poggi

    “Un caso di PTT in età pediatrica”

    Librone abstract XXXVIII Congresso nazionale AIEOP, Roma, Giugno 2013

30. C. Cerchione, G. Cerciello, R. Della Pepa, N. Pugliese, L. Marano, O. Vitagliano, M. Matarazzo, F. Pane, F. Alfinito

    Hematology, University of Naples “Federico II”, Naples, Italy

    “Combination of Deferasirox and Deferoxamine in management of iron overload in Myelodysplastic syndromes (MDS): an update in a hepatopatic patient”

    MDS Foundation 2013, Berlin, Abstract Book Leukemia Research, supplement May 2013

31. C. Cerchione, G. Cerciello, R. Della Pepa, N. Pugliese, L. Marano, O. Vitagliano, L. Luciano, F. Alfinito, F. Pane, A.M. Risitano

    Hematology, University of Naples “Federico II”, Naples, Italy

    “Role of Lenalidomide in management of Pure Red Cell Aplasia (PRCA) and Myelodysplastic Syndromes (MDS) with del (5q)”

    MDS Foundation 2013, Berlin, Abstract Book Leukemia Research, supplement May 2013

32. P. Danise, O. Vitagliano, C. Cerchione, I. Soriente, A.M. D’Arco, F. Pane, F. Alfinito

    Hematology, University of Naples “Federico II”, Naples, Italy

    “Erythropoietic aspects in MDS patients responders to ESAs treatment”

    MDS Foundation 2013, Berlin, Abstract Book Leukemia Research, supplement May 2013

33. Claudio Cerchione, Emanuela Madonna, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano

    BENDAMUSTINE: A NEW OPTION FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

34. Claudio Cerchione, Emanuela Madonna, Rossella Fabbricini, Luana Marano, Novella Pugliese, Fabrizio Pane, Lucio Catalano

    A NEW OPPORTUNITY IN RELAPLSED AND REFRACTORY MULTIPLE MYELOMA: PEGYLATED LIPOSOMAL

    DOXORUBICIN, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CED)

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

35. Claudio Cerchione, Emanuela Madonna, Rossella Fabbricini, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano

    TWENTY-FIVE MG LENALIDOMIDE EVERY OTHER DAY IN PATIENTS AFFECTED BY MULTIPLE MYELOMA AND RENAL FAILURE

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

36. Claudio Cerchione, Novella Pugliese, Luana Marano, Giuseppe Cerciello, Simona Avilia, Fabrizio Pane, Lucio Catalano

    PEGFILGRASTIM AS PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING CHEMOTHERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

37. Claudio Cerchione, Emanuela Madonna, Rossella Fabbricini, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano

    DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

38. Paolo Danise, Claudio Cerchione, Orsola Vitagliano, Ilaria Soriente, Alfonso Maria D'Arco, Fabrizio Pane, Fiorella Alfinito

    ERYTHROPOIETIC ASPECTS IN MDS PATIENTS RESPONDERS TO ESAS TREATMENT

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

39. Fiorella Alfinito, Orsola Vitagliano, Claudio Cerchione, Giovanna Giagnuolo, Ilaria Soriente, Alfonso Maria D'Arco, Paolo Danise, Fabrizio Pane

    ANALYSIS OF RESPONSE TO ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN 114 MYELODYSPLASTIC

    SYNDROME (MDS) PATIENTS FROM REGISTRO CAMPANO DELLE MIELODISPLASIE

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

40. Novella Pugliese, Claudio Cerchione, Francesco Grimaldi, Marta Raimondo, Maria Di Perna, Simona Pagliuca, Fabrizio Pane, Marco Picardi

    BENDAMUSTINE-BASED THERAPY IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA.

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

41. Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Luana Marano, Santa Errichiello, Claudio Cerchione, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    THE INTERFERON SCORE TOWARDS PREDICTION OF RESPONSIVNESS TO INTERFERON ALPHA IN ESSENTIAL THROMBOCYTHEMIA

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

42. Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Maddalena Raia, Claudio Cerchione, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    ALL-TRANS RETINOIC ACID POTENTIATES THE INHIBITORY EFFECTS OF INTERFERON ALPHA (IFN) ON CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN) PROGENITORS IN VITRO.

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

43. Giovanna Giagnuolo, Claudio Cerchione, Piera Angelillo, Orsola Vitagliano, Novella Pugliese, Luana Marano, Giorgia Battipaglia, Simona Avilia, Fiorella Alfinito, Giuseppe Cerciello, Fabrizio Pane

    BENEFITS OF THE USE OF AZACITIDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

44. Claudio Cerchione, Giuseppe Cerciello, Roberta Della Pepa, Novella Pugliese, Luana Marano, Orsola Vitagliano, Luigia Luciano, Fiorella Alfinito, Fabrizio Pane, Antonio Maria Risitano

    ROLE OF LENALIDOMIDE IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (MDS) WITH DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA)

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

45. Claudio Cerchione, Giuseppe Cerciello, Roberta Della Pepa, Novella Pugliese, Luana Marano, Orsola Vitagliano, Margherita Matarazzo, Fabrizio Pane, Fiorella Alfinito

    COMBINATION OF DEFERASIROX AND DEFEROXAMINE IN MANAGEMENT OF IRON OVERLOAD IN MYELODYSPLASTIC SYNDROMES (MDS): AN UPDATE IN A HEPATOPATIC PATIENT

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

46. Giusi Barra, Claudio Cerchione, Emanuela Madonna, G.Pasquale, A.Sementa, Fabrizio Pane, Lucio Catalano, Raffaele De Palma

    SPHINGOSINE KINASE 2 IS OVEREXPRESSED IN PATIENTS AFFECTED BY MULTIPLE MYELOMA

    Haematologica Abstract Book, EHA Stockholm, Vol.98 supplement no.1, June 2013

47. Claudio Cerchione, Giovanna Giagnuolo, Piera Angelillo, Simona Avilia, Orsola Vitagliano, Novella Pugliese, Luana Marano, Anna Pareto, Fiorella Alfinito, Fabrizio Pane, Giuseppe Cerciello

    BENEFITS OF THE USE OF AZACITIDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY

    XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book

48. Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Nicola Esposito, Claudio Cerchione, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    INTERFERON SIGNATURE PREDICTS RESPONSIVENESS IN ESSENTIAL THROMBOCYTHEMIA

    XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book

49. Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Maddalena Raia, Claudio Cerchione, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    IN VITRO SINERGISTIC INHIBITORY EFFECTS USING COMBINATION OF INTERFERON ALPHA AND ALL-TRANS RETINOIC ACID IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN)

    XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book

50. Claudio Cerchione, Emanuela Madonna, Luana Marano, Novella Pugliese, Elisa Seneca, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano

    MANAGEMENT OF MULTIPLE MYELOMA WITH BENDAMUSTINE: A FURTHER OPTION FOR RELAPSED AND REFRACTORY PATIENTS

    XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book

51. Claudio Cerchione, Novella Pugliese, Luana Marano, Giuseppe Cerciello, Simona Avilia, Elisa Seneca, Fabrizio Pane, Lucio Catalano

    PEGFILGRASTIM IN THE MANAGEMENT OF POSTCHEMOTHERAPY FEBRILE NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book

52. Claudio Cerchione, Paolo Danise, Orsola Vitagliano, Giuseppe Cerciello, Anna Pareto, Ilaria Soriente, Alfonso Maria D’Arco, Fabrizio Pane, Fiorella Alfinito

    EVALUATION OF ERYTHROPOIETIC ASPECTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES RESPONDERS TO ERYTRHOPOIESIS STIMULATING AGENTS (ESAs)

    XXVI Symposium IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases), Torino 2013, Abstract Book

53. Claudio Cerchione, Emanuela Madonna, Luana Marano, Novella Pugliese, Simona Avilia, Giuseppe Cerciello, Fabrizio Pane, Lucio Catalano

    MANAGEMENT OF MULTIPLE MYELOMA WITH BENDAMUSTINE: A FURTHER OPTION FOR RELAPSED AND REFRACTORY PATIENTS

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

54. Claudio Cerchione, Novella Pugliese, Luana Marano, Giuseppe Cerciello, Simona Avilia, Elisa Seneca, Fabrizio Pane, Lucio Catalano

    PEGFILGRASTIM IN THE MANAGEMENT OF POST-CHEMOTHERAPY FEBRILE NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

55. Paolo Danise, Claudio Cerchione, Orsola Vitagliano, Giuseppe Cerciello, Ilaria Soriente, Alfonso Maria D'Arco, Fabrizio Pane, Fiorella Alfinito

    EVALUATION OF ERYTHROPOIETIC ASPECTS IN PATIENTS WITH MYELODISPLASTIC SYNDROMES RESPONDERS TO ERYTHROPOIESIS STIMULATING AGENTS

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

56. Fiorella Alfinito, Claudio Cerchione, Orsola Vitagliano, Giovanna Giagnuolo, Giuseppe Cerciello, Ilaria Soriente, Alfonso Maria D'Arco, Paolo Danise, Fabrizio Pane

    ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

57. Novella Pugliese, Claudio Cerchione, Francesco Grimaldi, Marta Raimondo, Maria Di Perna, Simona Pagliuca, Fabrizio Pane, Marco Picardi

    EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMEN IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA.

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

58. Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Luana Marano, Santa Errichiello, Nicola Esposito, Claudio Cerchione, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    GENE EXPRESSION DRIVES INTERFERON TAILORED THERAPY IN ESSENTIAL THROMBOCYTHEMIA

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

59. Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Luana Marano, Maddalena Raia, Claudio Cerchione, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    SINERGISTIC INTERACTION BETWEEN ALL-TRANS RETINOIC ACID AND INTERFERON ALPHA IN VITRO MODEL OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN)

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

60. Claudio Cerchione, Giuseppe Cerciello, Roberta Della Pepa, Novella Pugliese, Luana Marano, Orsola Vitagliano, Luigia Luciano, Fiorella Alfinito, Fabrizio Pane, Antonio Maria Risitano

    MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (MDS) WITH DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA): ROLE OF LENALIDOMIDE

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

61. Claudio Cerchione, Vincenzo Russo, Francesca Tucci, Giuseppe Loffredo, Giuseppe Menna, Rosanna Parasole, Fara Petruzziello, Nicoletta Marra, Francesco Menna, Nicoletta Crescenzio, Vincenzo Poggi

    AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS): EXPERIENCE OF OUR AIEOP DEPARTMENT

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

62. Giovanna Giagnuolo, Claudio Cerchione, Piera Angelillo, Simona Avilia, Orsola Vitagliano, Novella Pugliese, Luana Marano, Fiorella Alfinito, Fabrizio Pane, Giuseppe Cerciello

    BENEFITS OF THE USE OF AZACITIDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

63. Fonti R, Pace L, Cerchione C, Catalano L, Seneca E, Madonna E, De Luca S, Pane F, Salvatore M, Del Vecchio S.

    ROLE OF 18-FDG-PET/CT, 99MTC-MIBI AND MRI IN THE PREDICTION OF OUTCOME OF MULTIPLE MYELOMA

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

64. Barra G, Cerchione C, Madonna E, Pasquale G, Sementa A, Pane F, Catalano L, De Palma R.

    OVEREXPRESSION OF SPHINGOSINE KINASE 2 IN MULTIPLE MYELOMA

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

65. Luana Marano, Novella Pugliese, Claudio Cerchione, Giuliana Beneduce, Concetta Quintarelli, Biagio De Angelis, Vincenzo Martinelli, Fabrizio Pane

    MUCOCUTANEOUS TOXICITY INDUCED BY HYDROXYUREA IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

66. Novella Pugliese, Luana Marano, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Nicola Esposito, Claudio Cerchione, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    INTERFERON ALPHA IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA

    Haematologica Abstract Book, SIE Verona, Vol.98 supplement no.3, October 2013

67. Novella Pugliese, Concetta Quintarelli, Biagio De Angelis, Luana Marano, Santa Errichiello, Nicola Esposito, Maddalena Raia, Claudio Cerchione, Luigi Del Vecchio, Marco Picardi, Vincenzo Martinelli, Fabrizio Pane

    THE INTERFERON SCORE TOWARDS INTERFERON ALPHA TAILORED THERAPY IN ESSENTIAL THROMBOCYTHEMIA

    ASH Abstract Book, December 2013

68. Claudio Cerchione, Mario Masarone, Marcello Persico, Giuliana Beneduce, Clementina Cimmino, Roberta Della Pepa, Serena Luponio, Ilaria Peluso, Novella Pugliese, Elisa Seneca, Marianna Notarangelo, Ciro Mainolfi, Marco Picardi, Fabrizio Pane, Amalia De Renzo

    ROLE OF PROPHYLAXIS WITH LAMIVUDINE IN MAINTENANCE TREATMENT WITH RITUXIMAB IN NON HODGKIN LYMPHOMA CD20+

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

69. Emanuela Madonna, Luigia Simeone, Marta Raimondo, Claudio Cerchione, Amalia De Renzo, Federico Chiurazzi, Fabrizio Pane

    SECONDARY MALIGNANCIES IN CHRONIC LYMPHOCYTIC LEUKEMIA: OUR EXPERIENCE

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

70. Claudio Cerchione, Emanuela Madonna, Anna Emanuele Pareto, Luana Marano, Novella Pugliese, Ilaria Peluso, Elisa Seneca, Giuseppe Cerciello, Simona Avilia, Santina Basile, Fabrizio Pane, Lucio Catalano

    MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH BENDAMUSTINE

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

71. Amalia De Renzo, Roberta Della Pepa, Serena Luponio, Claudio Cerchione, Giuliana Beneduce, Ilaria Migliaccio, Novella Pugliese, Clementina Cimmino, Elisa Seneca, Anna Emanuele Pareto, Orsola Vitgliano, Luigia Simeone, Fabrizio Pane, Giuseppe Spadaro

    RITUXIMAB-INDUCED HYPOGAMMAGLOBUINEMIA AND SUPPORTIVE INTRAVENOUS IG (IVIG) TREATMENT IN PATIENTS WITH NON HODGKIN LYMPHOMA

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

72. Amalia De Renzo, Claudio Cerchione, Fabiana Perna, Mario Masarone, Marcello Persico, Roberta Della Pepa, Clemetina Cimmino, Serena Luponio, Ilaria Peluso, Novella Pugliese, Elisa Seneca, Ciro Mainolfi, Ilario De Sio, Giuseppe Ciancia, Marco Picardi, Fabrizio Pane

    MANAGEMENT OF PRIMARY HEPATIC NON-HODGKIN’S LYMPHOMA AND CORRELATION WITH HCV INFECTION: EXCELLENT RESULTS WITH CONVENTIONAL CHEMOTHERAPY

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

73. Novella Pugliese, Elisa Seneca, Lucio Catalano, Marco Picardi, Clementina Cimmino, Claudio Cerchione, Maria Di Perna, Fabrizio Pane, Amalia De Renzo

    RISK OF SECOND MULTIPLE MYELOMA AFTER NON-HODGKIN AND HODGKIN LYMPHOMA

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

74. Claudio Cerchione, Clementina Cimmino, Novella Pugliese, Elisa Seneca, Roberta Della Pepa, Serena Luponio, Ciro Mainolfi, Fabrizio Pane, Amalia De Renzo

    MANAGEMENT OF RELAPSED/REFRACTORY LYMPHOMA WITH BRENTUXIMAB VEDOTIN: OUR EXPERIENCE IN THE TREATMENT OF YOUNG PATIENTS

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

75. Claudio Cerchione, Santina Basile, Vincenzo Russo, Elisa Seneca, Fabrizio Pane, Lucio Catalano

    PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

76. Claudio Cerchione, Serena Luponio, Roberta Della Pepa, Ilaria Migliaccio, Giuliana Beneduce, Novella Pugliese, Elisa Seneca, Ernesto Cimino, Antonio Coppola, Anna Maria Cerbone, Antonella Tufano, Marianna Notarangelo, Ilaria Peluso, Giovanni Di Minno, Fabrizio Pane, Amalia De Renzo

    ACQUIRED HEMOPHILIA IN ELDERLY PATIENTS WITH NON HODGKIN’S LYMPHOMA

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

77. Claudio Cerchione, Mario Masarone, Marcello Persico, Giuseppe Signoriello, Fabiana Perna, Clementina Cimmino, Novella Pugliese, Elisa Seneca, Ilaria Peluso, Marianna Notarangelo, Fabrizio Pane, Amalia De Renzo

    PROPHYLAXIS WITH LAMIVUDINE FOR THE PREVENTION OF REACTIVATION IN OCCULT HEPATITIS B (OBI) IN NHL : A COST-EFFECTIVE ANALYSIS

    Haematologica Abstract Book, EHA Milano, Vol.99 supplement no.1, June 2014

78. Claudio Cerchione, Orsola Vitagliano, Anna Emanuele Pareto, Ilaria Soriente, Paolo Danise, Fiorella Alfinito, Fabrizio Pane

    Analisi della risposta agli agenti eritrostimolanti in una coorte di pazienti affetti da syndrome mielodisplastica low-risk afferenti al Registro Campano per le MDS

    Libro dei lavori - Italian Red Cell Club 2014 – San Marcellino e Festo - Napoli

79. Cerchione C, Basile S, Russo V, Seneca E, Pane F, Catalano L

    MANAGEMENT OF POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: ROLE OF PEGFILGRASTIM

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

80. Alfinito F, Cerchione C, Vitagliano O, Pareto AE, Barca R, Cerciello G, Soriente I, D’Arco AM, Pane F, Danise P

    MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

81. Pugliese N, Seneca E, Catalano L, Picardi M, Cimmino C, Luponio S, Cerchione C, Di Perna M, Pane F, De Renzo A

    INCIDENCE OF MULTIPLE MYELOMA FOLLOWING THERAPY FOR NON-HODGKIN AND HODGKIN LYMPHOMA

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

82. Cerchione C, Masarone M, Persico M, Beneduce G, Cimmino C, Luponio S, Pugliese N, Seneca E, Notarangelo M, Mainolfi C, Picardi M, Pane F

    PROPHYLAXIS WITH LAMIVUDINE IN MAINTENANCE TREATMENT WITH RITUXIMAB IN NON HODGKIN LYMPHOMA CD20+

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

83. Cerchione C, De Renzo A, Perna F, Masarone M, Persico M, Della Pepa R, Cimmino C, Luponio S, Pugliese N, Seneca E, Peluso I, Ciancia G, Mainolfi C, De Sio I, Picardi M, Pane F

    PRIMARY HEPATIC NON-HODGKIN’S LYMPHOMA AND CORRELATION WITH HCV INFECTION: EXCELLENT RESULTS WITH CONVENTIONAL CHEMOTHERAPY

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

84. Cerchione C, Madonna E, Pareto AE, Basile S, Peluso I, Vitagliano O, Cimmino C, Simeone L, Seneca E, Pugliese N, Marano L, Pane F, Catalano L

    ROLE OF BENDAMUSTINE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

85. Cerchione C, Cimmino C, Luponio S, Della Pepa R, Migliaccio I, Beneduce G, Pugliese N, Seneca E, Cimmino E, Coppola A, Cerbone AM, Tufano A, Notarangelo M, Peluso I, Di Minno G, Pane F, De Renzo A

    MANAGEMENT OF ACQUIRED HEMOPHILIA IN ELDERLY PATIENTS WITH NON HODGKIN’S LYMPHOMA

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

86. Cerchione C, Masarone M, Persico M, Perna F, Cimmino C, Peluso I, Notarangelo M, Pane F, De Renzo A

    COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAMIVUDINE FOR THE PREVENTION OF REACTIVATION IN OCCULT HEPATITIS B (OBI) IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING CHEMOTHERAPY WITH AND WITHOUT RITUXIMAB

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

87. Cerchione C, Cimmino C, Pugliese N, Seneca E, Mainolfi C, Pane F, De Renzo A

    BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY LYMPHOMA: OUR EXPERIENCE IN THE TREATMENT OF YOUNG PATIENTS

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

88. De Renzo A, Della Pepa R, Luponio S, Cerchione C, Beneduce G, Migliaccio I, Pugliese N, Cimmino C, Seneca E, Pareto AE, Vitagliano O, Simeone L, Pane F, Spadaro G

    SUPPORTIVE INTRAVENOUS IG (IVIG) TREATMENT IN RITUXIMAB-INDUCED HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH NON HODGKIN LYMPHOMA

    Haematologica Abstract Book, SIES Rimini, Vol.99 supplement no.2, October 2014

89. Cerchione C, Vitagliano O, Simeone L, Pareto AE, Soriente I, D’Arco AM, Danise P, Alfinito F, Pane F

    MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE

    Leuk Res Vol. 39 Suppl 1, S1-S166 (13th International Symposium on Myelodysplastic Syndromes (MDS))

90. Cerchione C, De Renzo A, Masarone M, Cimmino C, Raimondo M, Signoriello G, Notarangelo M, Giagnuolo G, Persico M, Pane F

    COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAMIVUDINE FOR PREVENTION OF REACRIVATION IN OCCULT HEPATITIS B (OBI) IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING CHEMOTHERAPY

    Haematologica Abstract Book, EHA Vienna, June 2015

91. Cerchione C, Vitagliano O, Simeone L, Pareto AE, Soriente I, D’Arco AM, Danise P, Alfinito F, Pane F

    MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE

    Haematologica Abstract Book, EHA Vienna, June 2015

92. Cerchione C, De Renzo A, Masarone M, Cimmino C, Persico M, Notarangelo M, Perna F, Mainolfi C, De Sio I, Ciancia G, Picardi M, Pane F

    MANAGEMENT OF PRIMARY HEPATIC NON HODGKIN’S LYMPHOMA AND CORRELATION WITH HCV INFECTION: EXCELLENT RESULTS WITH CONVENTIONAL CHEMOTHERAPY

    Haematologica Abstract Book, EHA Vienna, June 2015

93. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F

    BENDAMUSTINE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE

    Haematologica Abstract Book, EHA Vienna, June 2015

94. Cerchione C, Catalano L, Pareto A.E., Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F

    BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE

    Leuk Res Vol 15, Suppl 3, September 2015

95. Cerchione C, Catalano L, Pareto A.E., Marano L, Basile S, Pane F

    PEGYLATED DOXORUBICINE, CYCLOPHOSPHAMIDE AND DEXAMETASONE (CED): A NEW OPPORTUNITY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

    Leuk Res Vol 15, Suppl 3, September 2015

96. Cerchione C, De Renzo A, Cimmino C, Raimondo M, Marano L, Madonna E, Di Perna M, Russo V, Mainolfi C, Picardi M, Pane F

    BRENTUXIMAB VEDOTIN IN THE MANAGEMENT OF RELAPSED/REFRACTORY LYMPHOMA IN YOUNG PATIENTS: OUR REAL-LIFE EXPERIENCE

    Haematologica Abstract Book, Sie Firenze, October 2015

97. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F

    BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE

    Haematologica Abstract Book, Sie Firenze, October 2015

98. Cerchione C, Vitagliano O, Simeone L, Pareto AE, Cerciello G, Soriente I, D’Arco AM, Danise P, Alfinito F, Pane F

    MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS (ESAs): EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE

    Haematologica Abstract Book, Sie Firenze, October 2015

99. Claudio Cerchione, Catalano L, Pareto AE, Marano L, Basile S, Pane F

    PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CED): A NEW OPPORTUNITY IN RELAPLSED AND REFRACTORY MULTIPLE MYELOMA

    Haematologica Abstract Book, Sie Firenze, October 2015

100. Cerchione C, De Renzo A, Masarone M, Cimmino C, Raimondo M, Signoriello G, Notarangelo M, Giagnuolo G, Di Perna M, Russo V, Persico M, Pane F

     COST-EFFECTIVE ANALYSIS OF PROPHYLAXIS WITH LAMIVUDINE FOR PREVENTION OF REACRIVATION IN OCCULT HEPATITIS B IN PATIENTS WITH NON HODGKIN LYMPHOMA CD20+ UNDERGOING CHEMOTHERAPY

     Haematologica Abstract Book, Sie Firenze, October 2015

101. Cerchione C, De Renzo A, Masarone M, Cimmino C, Persico M, Notarangelo M, Perna F, Mainolfi C, De Sio I, Ciancia G, Picardi M, Pane F

     MANAGEMENT OF PRIMARY HEPATIC NON-HODGKIN’S LYMPHOMA (PHL)

     Haematologica Abstract Book, Sie Firenze, October 2015

102. Cerchione C, De Renzo A, Cimmino C, Raimondo M, Di Perna M, Russo V, Picardi M, Pane F

     PEGFILGRASTIM IN PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING RITUXIMAB-BENDAMUSTINE TREATMENT IN INDOLENT NON HODGKIN LYMPHOMA: A REAL-LIFE EXPERIENCE

     Haematologica Abstract Book, Sie Firenze, October 2015

103. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F

     “Bendamustine-Bortezomib-Desametasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A real-life experience”

     Blood December 3, 2015, 126 (23)

104. Cerchione C, De Renzo A, Masarone M, Cimmino C, Di Perna M, Signoriello G, Persico M, Pane F

     Lamivudine for prevention of reactivation in occult hepatitis B in patients with non-Hodgkin Lymphoma CD20+ undergoing chemotherapy: a cost-effective analysis

     Haematologica Abstract Book, EHA Copenaghen, June 2016

105. Cerchione C, Vitagliano O, Pareto AE, Di Perna M, Cerciello G, Soriente I, Alfinito F, Pane F

     Management of myelodysplastic syndromes with Erythropoiesis stimulating agents (ESAs): a real-life experience

     Haematologica Abstract Book, EHA Copenaghen, June 2016

106. Cerchione C, De Renzo A, Masarone M, Cimmino C, Della Pepa R, Di Perna M, Mainolfi C, De Sio I, Ciancia G, Persico M, Pane F

     Management of primary hepatic non-Hodgkin’s lymphoma (PHL)

     Haematologica Abstract Book, EHA Copenaghen, June 2016

107. Gravetti A, Cerchione C, Casoria A, Pugliese N, Marano L, De Gregorio F, Di Perna M, Picardi M, Martinelli V, Pane F

     Use of combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

     Haematologica Abstract Book, EHA Copenaghen, June 2016

108. De Nisco M, Cerchione C, Martinelli V, Pugliese N, Pedatella S, Catalano L, Manfra M, Marra N, Iula VD, Pagano F, Picardi M, Pane F

     An HPLC and 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance

     Haematologica Abstract Book, EHA Copenaghen, June 2016

109. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Ferrara F, Pane F

     Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience

     Haematologica Abstract Book, EHA Copenaghen, June 2016

110. Cerchione C, De Renzo A, Cimmino C, Raimondo M, Di Perna M, Picardi M, Pane F

     Pegfilgrastim in primary prophylaxis of febrile neutropenia during rituximab-bendamustine treatment in indolent non Hodgkin lymphoma: a real-life experience

     Haematologica Abstract Book, EHA Copenaghen, June 2016

111. Cerchione C, Nappi D, Salvatore D, Migliaccio I, Pane F, Catalano L

     Pegfilgrastim versus filgrastim in the management of post-chemotherapy neutropenia in relapsed and refractory multiple myeloma in treatment with BVD (bendamustine-bortezomib-dexamethasone)

     Haematologica Abstract Book, EHA Copenaghen, June 2016

112. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Caprioli V, Frieri C, Pane F, Picardi M

     Front-line central vascular access devices in acute leukemias – peripherally inserted central catether (PICC) versus traditional central venous catether (CVC): a phase IV randomized trial (NCT02405728)

     Haematologica Abstract Book, EHA Copenaghen, June 2016

113. Cerchione C, Di Perna M, Pugliese N, Della Pepa R, Raimondo M, Pane F, Picardi M

     Bendamustine-brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma

     Haematologica Abstract Book, EHA Copenaghen, June 2016

114. Cerchione C, Catalano L, Pareto AE, Basile S, Peluso I, Marano L, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F

     Role of Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience

     SIICA: Multiple Myeloma 2016 – Perspectives for a paradigm change – Catanzaro – June 2016

115. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M

     Front-line central vascular access devices in acute leukemias – peripherally inserted central catether (PICC) versus traditional central venous catether (CVC): a phase IV randomized trial (NCT02405728)

     ASH meeting on hematologic malignancies, Chicago, September 2016

116. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Raimondo M, Pane F, Picardi M

     Bendamustine-brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma

     ASH meeting on hematologic malignancies, Chicago, September 2016

117. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F

     Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience

     ESH 3^rd International Conference on Multiple Myeloma – Milan – October 2016 (Oral presentation)

118. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Raimondo M, Pane F, Picardi M

     Bendamustine-brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma

     Haematologica Abstract Book, SIES Rimini, October 2016

119. Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D’Arco AM, Danise P, Alfinito F, Pane F

     Management of myelodysplastic syndromes with Erythropoiesis stimulating agents (ESAs) : evalutation of erythropoietic aspects and analysis of response

     Haematologica Abstract Book, SIES Rimini, October 2016

120. Cerchione C, Luciano L, Cimmino C, Memoli M, Pane F

     Imatinib mesylate and cardiac function

     Haematologica Abstract Book, SIES Rimini, October 2016

121. Cerchione C, De Renzo A, Masarone M, Cimmino C, Persico M, Notarangelo M, Rosato V, Della Pepa R, Pugliese N, Mainolfi C, De Sio I, Pane F, Picardi M

     Primary hepatic non Hodgkin lymphoma: high prevalence of hepatitis C virus infection and efficacy of the conventional six courses of anthracycline-based chemotherapy

     Haematologica Abstract Book, SIES Rimini, October 2016

122. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Caprioli V, Frieri C, Pane F, Picardi M

     Front-line central vascular access devices in acute leukemias – peripherally inserted central catether (PICC) versus traditional central venous catether (CVC): a phase IV randomized trial (NCT02405728)

     Haematologica Abstract Book, SIES Rimini, October 2016

123. Cerchione C, Gravetti A, Casoria A, Pugliese N, Marano L, Raimondo M, Picardi M, Martinelli V, Pane F

     Use of combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

     Haematologica Abstract Book, SIES Rimini, October 2016

124. De Nisco M, Cerchione C, Martinelli V, Pugliese N, Pedatella S, Catalano L, Manfra M, Marra N, Iula VD, Pagano F, Picardi M, Bolognese A, Pane F

     An HPLC and 1H NMR Study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance

     Haematologica Abstract Book, SIES Rimini, October 2016

125. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Ferrara F, Pane F

     Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A real-life experience

     Haematologica Abstract Book, SIES Rimini, October 2016

126. Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, Migliaccio I, Picardi M, Pane F

     Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with Bendamustine-Bortezomib-Dexamethasone

     Haematologica Abstract Book, SIES Rimini, October 2016

127. Cerchione C, Di Perna M, Nappi D, Zacheo I, Pane F, Catalano L

     Lenalidomide twenty-five mg every other day in patients affected by multiple myeloma and renal failure

     Haematologica Abstract Book, SIES Rimini, October 2016

128. Pugliese N, Di Perna M, Cozzolino I, Ciancia G, Pettinato G, Varone V, Zeppa P, Masone S, Cerchione C, Della Pepa R, Salvatore C, Pane F, Picardi M

     Randomized Comparison of Power Doppler Ultrasonography-Guided-Core-Needle Biopsy with Open Surgical Biopsy for the Characterization of Lymphadenopathies in patients with suspected lymphoma

     Blood 2016 128: 685 (ASH 2016 Abstract Book)

129. Cerchione C, Di Perna M, Nappi D, Zacheo I, Pane F, Catalano L

     Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience

     16^TH International Myeloma Workshop 2017, New Delhi, India

130. Cerchione C, Di Perna M, Nappi D, Zacheo I, Pane F, Catalano L

     Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience

     16^TH International Myeloma Workshop 2017, New Delhi, India

131. Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D’Arco AM, Danise P, Alfinito F, Pane F

     Management of myelodysplastic syndromes with erythropoiesis stimulating agents (ESAs) in real-life experience: an update from RECAMDS

     Leuk Res Abstract Book, 14^TH International Symposium on Myelodysplastic Syndromes (MDS 2017), Valencia, May 2017

132. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M

     High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma

     14^TH International Conference on Malignant Lymphoma, Lugano, June 2017

133. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M

     Front-line vascular access devices in acute leukemias – peripherally inserted central catheter (PICC) versus traditional center venous catheter (CVC): a phase IV randomized trial (NCT02405728)

     Oral communication - Haematologica Abstract Book, EHA Madrid, June 2017

134. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Marano L, Peluso I, Simeone L, Vitalgiano O, Palmieri S, Rocco S, Ferrara F, Pane F

     Bendamustine-bortezomib-dexamethasone (BVD) in the management of relapsed and refractory multiple myeloma: a real-life experience

     Haematologica Abstract Book, EHA Madrid, June 2017

135. Della Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, Cerchione C, Pane F

     Nodular lymphocyte predominant Hodgkin lymphoma: a new risk adapted treatment strategy based on Rituximab

     Haematologica Abstract Book, EHA Madrid, June 2017

136. Cerchione C, Catalano L, Pareto AE, Nappi D, Peluso I, Ferrara K, Di Perna M, Zacheo I, Pane F

     Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience

     Haematologica Abstract Book, EHA Madrid, June 2017

137. Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Catalano L, Nappi D, Ciancia G, Pettinato G, Pane F, Martinelli V

     Use of combined oral fentanyl citrate (Actiq) and midazolam as premedication for bone marrow biopsy in patients with hematological malignancies: a randomized controlled patient blinded clinical trial

     Haematologica Abstract Book, EHA Madrid, June 2017

138. Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D’Arco AM, Danise P, Alfinito F, Pane F

     Management of myelodysplastic syndromes with erythropoiesis stimulating agents (ESAs) in real-life experience: an update from RECAMDS

     Haematologica Abstract Book, EHA Madrid, June 2017

139. Puglese N, Simeone L, Della Pepa R, Giordano C, Cappuccio I, Zacheo I, Campagna G, Cerchione C, Zeppa P, Salvatore C, Pane F, Picardi M

     Impact on survival of early detection of recurrence in the follow-up of high risk Hodgkin lymphoma in first complete remission

     Haematologica Abstract Book, EHA Madrid, June 2017

140. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M

     High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma

     Haematologica Abstract Book, EHA Madrid, June 2017

141. Cerchione C, Ferrara K, Peluso I, Nappi D, Di Perna M, Zacheo I, Pareto AE, Pane F, Catalano L

     Carfilzomib-lenalidomide-dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience

     Haematologica Abstract Book, EHA Madrid, June 2017

142. Cerchione C, Catalano L, Pareto AE, Nappi D, Peluso I, Ferrara K, Di Perna M, Zacheo I, Romano A, Pane F

     Full standard doses of lenalidomide in bortezomib-refractory Multiple Myeloma patients affected by renal failure: a real-life experience

     Clinical Myeloma & Lymphoma, Vol. 17, Suppl. 2, September 2017

143. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Romano A, Ferrara F, Pane F

     Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience

     Clinical Myeloma & Lymphoma, Vol. 17, Suppl. 2, September 2017

144. Cerchione C, Ferrara K, Peluso I, Nappi D, Di Perna M, Zacheo I, Pareto AE, Pane F, Catalano L

     Front-line vascular access devices in acute leukemias – Peripherally Inserted Central Catheter (PICC) versus traditional Central Venous Catether (CVC): A Phase IV Randomized Trial (NCT02405728)

     Clinical Myeloma & Lymphoma, Vol. 17, Suppl. 2, September 2017

145. Cerchione C, Picardi M, Di Perna M, Della Pepa R, Pugliese N, Pane F

     Front-line vascular access devices in acute leukemias – peripherally inserted central catheter (PICC) versus traditional center venous catheter (CVC): a phase IV randomized trial (NCT02405728)

     Oral communication - Haematologica Abstract Book, SIE Roma, October 2017

146. Palmieri S, Rocco S, Migliaccio I, Cerchione C, Catalano L, Ferrara K, Peluso I, Monaco G, Farina G, Gagliardi A, Barone M, Esposito D, Amico V, Arcamone M, Fontana R, Sica A, Pane F, Ferrara F

     KRD (Carfilzomib plus Lenalidomide plus Dexamethasone) in relapsed or refractory Multiple Myeloma in Campania Region: a one-year survey

     Haematologica Abstract Book, SIE Roma, October 2017

147. Cerchione C, Picardi M, Pugliese N, Della Pepa R, Cappuccio I, Campagna G, Fanelli F, Gravetti A, Casoria A, Catalano L, Nappi D, Ciancia G, Pettinato G, Pane F, Martinelli V

     Use of combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

     Haematologica Abstract Book, SIE Roma, October 2017

148. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Romano A, Ferrara F, Pane F

     Bendamustine-Bortezomib-Dexamethasone (BVD) in the management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience

     Haematologica Abstract Book, SIE Roma, October 2017

149. Della Pepa R, Picardi M, Giordano C, Zacheo I, Pugliese N, Cerchione C, Pane F

     Nodular lymphocyte predominant Hodgkin lymphoma: a new risk adapted treatment strategy based on Rituximab

     Haematologica Abstract Book, SIE Roma, October 2017

150. Cerchione C, Picardi M, Di Perna M, Della Pepa R, Pugliese N, Della Pepa R, Pane F

     High-dose bendamustine plus brentuximab vedotin is effective and has a favourable toxicity profile in the treatment of refractory or relapsed Hodgkin lymphoma

     Haematologica Abstract Book, SIE Roma, October 2017

151. Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Pane F, Catalano L

     Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma: a real-life experience

     Haematologica Abstract Book, SIE Roma, October 2017

152. Cerchione C, Catalano L, Pareto AE, Nappi D, Peluso I, Ferrara K, Di Perna M, Zacheo I, Pane F

     Lenalidomide at the dose of twenty-five mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience

     Haematologica Abstract Book, SIE Roma, October 2017

153. Cerchione C, Vitagliano O, Cerciello G, Pareto AE, Di Perna M, Soriente I, D’Arco AM, Danise P, Alfinito F, Pane F

     Management of low-risk myelodysplastic syndromes with erythropoiesis stimulating agents (ESAs) in real-life experience: an update from RECAMDS (Registro Campano delle sindromi mielodisplastiche)

     Haematologica Abstract Book, SIE Roma, October 2017

154. Puglese N, Simeone L, Della Pepa R, Giordano C, Cappuccio I, Zacheo I, Campagna G, Cerchione C, Zeppa P, Salvatore C, Pane F, Picardi M

     Impact on survival of early detection of recurrence in the follow-up of high risk Hodgkin lymphoma in first complete remission

     Haematologica Abstract Book, SIE Roma, October 2017

155. Cerchione C, Di Perna M, Della Pepa R, Pugliese N, Pane F, Picardi M

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     Haematologica Abstract Book, SIE Roma, October 2017

156. Cerchione C, Ferrara K, Peluso I, Nappi D, Di Perna M, Zacheo I, Pareto AE, Pane F, Catalano L

     Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience

     Haematologica Abstract Book, SIE Roma, October 2017

157. Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Ciancia G, Pane F, Martinelli V

     Combined oral fentanyl citrate (Actiq) and midazolam as premedication for bone marrow aspiration and biopsy in patients with hematological malignancies: a randomized, controlled clinical trial

     VII Corso di Alta Formazione in terapia del dolore, Abstract Book, Capri (NA); October 2017

158. Cerchione C, Nappi D, Pareto AE, Romano A, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L

     Safety and comfort of domestic bortezomib injection in real-life experience

     Blood December 2017 (ASH 2017 Abstract Book)

159. Cerchione C, Di Perna M, Pugliese N, Della Pepa R, Pane M, Picardi M

     High-dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma

     Blood December 2017 (ASH 2017 Abstract Book)

160. Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Ciancia G, Pane F, Martinelli V

     Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

     Blood December 2017 (ASH 2017 Abstract Book)

161. Palmieri S, Rocco S, Migliaccio I, Cerchione C, Catalano L, Ferrara K, Peluso I, Monaco G, Farina G, Gagliardi A, Barone M, Esposito D, Amico V, Arcamone M, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F

     KRD (Carfilzomib plus lenalidomide plus dexamethasone) in relapsed or refractory multiple myeloma: a real life survey in Campania region in southern Italy

     Haematologica Abstract Book, EMN Turin, April 2018, s1

162. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Romano A, Palmieri S, Rocco S, Monaco G, Romano A, Pane F, Ferrara F

     Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma

     Haematologica Abstract Book, EMN Turin, April 2018, s1

163. Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Pane F, Catalano L

     Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

     Haematologica Abstract Book, EMN Turin, April 2018, s1

164. Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Pane F, Catalano L.

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     Haematologica Abstract Book, EMN Turin, April 2018, s1

165. Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L

     Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience

     Haematologica Abstract Book, EMN Turin, April 2018, s1

166. Cerchione C, Nappi D, Pareto AE, Romano A, Di Perna M, Zacheo I, Picardi M, Pane F, Catalano L

     Safety and comfort of domestic bortezomib injection in real-life experience

     Haematologica Abstract Book, EMN Turin, April 2018, s1

167. Pugliese N, Giordano C, Nappi D, Luciano L, Cerchione C, Annunziata M, Casale B, Crisà E, Villa MR, Pezzullo L, Iovine M, Picardi M, Simeone L, Pane F, Martinelli V

     Ruxolitinib and hydroxyurea combination for the treatment of myelofibrosis

     HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

168. Raimondo M, Della Pepa R, Giordano C, Pugliese N. Cerchione C, Trastulli F, Mortaruolo C, Zacheo I, Picardi M, Pane F

     Efficacy and safety of high dose bendamustine plus brentuximab vedotin in refractory or relapsed classical Hodgkin lymphoma: a single center experience

     HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

169. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Monaco G, Romano A, Pane F, Ferrara F

     Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma

     HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

170. Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Romano A, Pane F, Catalano L

     Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

     HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

171. Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L

     Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience

     HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

172. Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

173. Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Ciancia G, Pettinato G, Pane F, Martinelli V

     Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

     HemaSphere Abstract Book, EHA Stockholm, June 2018, 2 (S1)

174. Cerchione C, Catalano L, Nappi D, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Romano A, Ferrara F, Pane F

     Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma

     Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018

175. Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Pane F, Catalano L

     Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

     Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018

176. Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018

177. Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.

     Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone

     Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018

178. Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Ciancia G, Pane F, Martinelli V

     Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

     Clinical Myeloma & Lymphoma, Vol. 18, Suppl. 1, September 2018

179. Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Romano A, Pane F, Catalano L

     Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

     ESH 4^rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018

180. Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     ESH 4^rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018

181. Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.

     Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone

     ESH 4^rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018

182. Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L

     Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience

     ESH 4^rd International Conference on Multiple Myeloma – Mandelieu, France – October 2018

183. Cerchione C, Ferrara K, Peluso I, Di Perna M, Zacheo I, Nappi D, Pareto A. E., Romano A, Pane F, Catalano L

     Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

     Hematology Abstract Book, SIES, October 2018 (Suppl. 2)

184. Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     Hematology Abstract Book, SIES, October 2018 (Suppl. 2)

185. Cerchione C, Picardi M, Pugliese N, Della Pepa R, Gravetti A, Casoria A, Nappi D, Ciancia G, Pane F, Martinelli V

     Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy

     Hematology Abstract Book, SIES, October 2018 (Suppl. 2) – Oral communication

186. Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.

     Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone

     Hematology Abstract Book, SIES, October 2018 (Suppl. 2)

187. Cerchione C, Catalano L, Pareto AE, Basile S, Marano L, Peluso I, Simeone L, Vitagliano O, Palmieri S, Rocco S, Monaco G, Romano A, Pane F, Ferrara F

     Bendamustine-Bortezomib-Dexamethasone (BVD) in heavily pretreated Multiple Myeloma

     Hematology Abstract Book, SIES, October 2018 (Suppl. 2)

188. Cerchione C, Pareto AE, Zacheo I, Di Perna M, Nappi D, Peluso I, Ferrara K, Romano A, Pane F, Catalano L

     Bortezomib, lenalidomide and dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience

     Hematology Abstract Book, SIES, October 2018 (Suppl. 2)

189. Cerchione C, Nappi D, Pareto AE, Migliaccio I, Zacheo I, Di Perna M, Peluso I, Ferrara K, Romano A, Pane F, Catalano L.

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     Blood December 2018 (ASH 2018 Abstract Book)

190. Cerchione C, Nappi D, Pareto AE, Picardi M, Pane F, Catalano L.

     Pegfilgrastim versus filgrastim in the management of therapy-related neutropenia in relapsed and refractory multiple myeloma in treatment with pomalidomide-dexamethasone

     Blood December 2018 (ASH 2018 Abstract Book)

191. Samantha Bruno, Martina Pazzaglia, Claudio Cerchione, Simona Soverini, Michele Cavo, Lorenzo Montanaro, Giorgia Simonetti, Giovanni Martinelli. Deep hypoxia and the genomic background cooperate to shape the metabolic profıle of acute myeloid leukemia cells. AACR 2019 Proceedings.
192. Giovanni Martinelli, Stefania Paolini, Claudio Cerchione, Alessandra Santoro, Valentina Robustelli, Simona Soverini, Caterina De Benedittis, Enrica Imbrogno, Andrea Ghelli Luserna Di Rora, Sarah Parisi, Chiara Sartor, Giovanni Marconi, Silvia Lo Monaco, Maria Chiara Abbenante, Maria Chiara Fontana, Antonella Padella, Anna Ferrari, Giorgia Simonetti, Elena Tenti, Federica Frabetti, Francesca Volpato, Samantha Bruno, Fabiana Mammoli, Maria Teresa Bocchicchio, Carmen Baldazzi, Cristina Papayannidis. Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience. AACR 2019 Proceedings.
193. Giorgia Simonetti, Antonella Padella, Eugenio Fonzi, Martina Pazzaglia, Margherita Perricone, Maria Chiara Fontana, Samantha Bruno, Maria Teresa Bochicchio, Eugenia Franchini, Jacopo Nanni, Giovanni Marconi, Italo F. do Valle, Rossella De Tommaso, Anna Ferrari, Enrica Imbrogno, Claudio Cerchione, Cristina Papayannidis, Emanuela Ottaviani, Daniel Remondini, Giovanni Martinelli. Metabolic profıling defınes a new characterization of acute myeloid leukemia and identifıes NPM1-mutated cases as a distinct subgroup. AACR 2019 Proceedings.
194. C. Cerchione. BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA. Comy 2019 (Paris).
195. C. Cerchione. CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA. Comy 2019 (Paris).
196. C. Cerchione. POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA. Comy 2019 (Paris).
197. PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE. C. Cerchione. Comy 2019 (Paris).
198. Claudio Cerchione, Giovanni Martinelli, Davide Nappi, Anna Emanuele Pareto, Maria Di Perna, Katia Ferrara, Fabrizio Pane, Lucio Catalano, Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma. ASCO 2019 Chicago. J Clin Oncol 37, 2019 (suppl; abstr e19522)
199. Claudio Cerchione, Giovanni Martinelli, Lucio Catalano, Novella Pugliese, Roberta Della Pepa, Angela Gravetti, Davide Nappi, Fabrizio Pane, Vincenzo Martinelli; Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy. ASCO 2019 Chicago. J Clin Oncol 37, 2019 (suppl; abstr e18313)
200. Giovanni Martinelli, Stefania Paolini, Claudio Cerchione, Alessandra Santoro, Valentina Robustelli, Simona Soverini, Caterina De Benedittis, Enrica Imbrogno, Andrea Ghelli Luserna di Rorà, Sarah Parisi, Chiara Sartor, Giovanni Marconi, Silvia Lo Monaco, Maria Chiara Abbenante, Maria Chiara Fontana, Antonella Padella, Anna Ferrari, Giorgia Simonetti, Cristina Papayannidis. Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience. ASCO 2019 Chicago. J Clin Oncol 37, 2019 (suppl; abstr e18522).
201. C. Cerchione, V. Guadagnuolo, C. Papayannidis, I. Iacobucci, A. Padella, G. Simonetti, S. Paolini, M. Abbenante, S. Parisi, F. Volpato, M. C. Fontana, E. Ottaviani, N. Testoni, C. Baldazzi, M. Delledonne, C. Filì, M. Malagola, F. Cattina, S. Bernardi, D. Russo, G. Martinelli. A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
202. G. Simonetti, A. Padella, C. Mengucci, E. Fonzi, G. Picone, M. Pazzaglia, M. Perricone, M. Fontana, S. Bruno, M. T. Bochicchio, E. Franchini, J. Nanni, G. Marconi, I. F. do Valle, R. De Tommaso, A. Ferrari, M. Ghetti, R. Napolitano,

     C. Papayannidis, A. Ghelli Luseran di Rorà, C. Cerchione, E. Ottaviani, G. Castellani, D. Remondini, F. Capozzi, G. Martinelli. A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)

203. C. Cerchione, G. Martinelli, S. Rocco, S. Palmieri, D. Nappi, A. E. Pareto, F. Pane, L. Catalano, F. Ferrara, BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/

     NEW ARM IN NOVEL AGENTS‘ WORLD. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)

204. C. Cerchione, G. Martinelli, D. Nappi, A. E. Pareto, M. Di Perna, K. Ferrara, A. Ferrari, G. Simonetti, F. Pane, L. Catalano. CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY

     MULTIPLE MYELOMA. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)

205. C. Cerchione, G. Martinelli, L. Catalano, N. Pugliese, R. Della Pepa, A. Gravetti, D. Nappi, F. Pane, V. Martinelli. COMBINED ORAL ANALGESIA AND ANXIOLYSIS FOR PAIN ASSOCIATED WITH BONE MARROW ASPIRATION

     AND BIOPSY. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)

206. C. Cerchione, G. Martinelli, I. Soriente, A. M. D’Arco, P. Danise, G. Cerciello, F. Pane, F. Alfinito. ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES: RECAMDS TRIAL. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
207. C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, F. Pane, L. Catalano. PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF THERAPY-RELATED NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
208. C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, M. Di Perna, K. Ferrara, A. Ferrari, G. Simonetti, F. Pane, L. Catalano. POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
209. C. Cerchione, V. Guadagnuolo, C. Papayannidis, M.C. Fontana, A. Padella, I. Iacobucci, G. Simonetti, G. Marconi, S. Paolini, M. Abbenante, S. Parisi, F. Volpato, E. Ottaviani, M. Delledonne, G. Biasco, G. Martinelli, SNP ARRAY REVEALS A NEW DELETION OF JAK2 IN AML PATIENTS. HemaSphere Abstract Book, EHA Amsterdam, June 2019, (S1)
210. G. Simonetti, A. Padella, C. Mengucci, E. Fonzi, G. Picone, M. Pazzaglia, M. Perricone, M.C. Fontana, S. Bruno, M.T. Bochicchio, E. Franchini, J. Nanni, G. Marconi, I.F. do Valle, R. De Tommaso, A. Ferrari, M. Ghetti, R. Napolitano, C. Papayannidis, C. Cerchione, E. Ottaviani, G. Castellani, D. Remondini, F. Capozzi, G. Martinelli. INTRACELLULAR AND SYSTEMIC METABOLIC PROFILING OF ACUTE MYELOID LEUKEMIA IMPROVES GENOMIC CLASSIFICATION AND SUGGESTS NOVEL THERAPEUTIC TARGETS. Hematologica Abstract Book October 2019 (SIE) Suppl.2
211. C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, M. Di Perna, K. Ferrara, G. Musuraca, A. Lucchesi, A. Ferrari, G. Simonetti, F. Pane, L. Catalano. CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA. Hematologica Abstract Book October 2019 (SIE) Suppl.2
212. A. Ferrari, S. Vitali, C. Baldazzi, G. Ferrari, V. Robustelli, A. Ghelli, E. Fonzi, M. Tebaldi, S. Salvi, C. Papayannidis, S. Paolini, A. Padella, M.T. Bochicchio, G. Pasquini, G. Simonetti, G. Musuraca, D. Cangini, B.M. Giannini, C. Cerchione, A. Santoro, J.M. Hernández-Rivas, D. Calistri, N. Testoni, D. Remondini, G. Martinelli. ADULT TRIPLE NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA FUSION DETECTION: THE CHALLENGE FOR ALTERNATIVE THERAPIES. Hematologica Abstract Book October 2019 (SIE) Suppl.2
213. A. Ferrari, S. Vitali, V. Robustelli, A. Ghelli, C. Baldazzi, S. Righi, E. Fonzi, S. De Matteis, M. Ghetti, R. Napolitano, M. Tebaldi, S. Salvi, C. Papayannidis, G. Marconi, S. Paolini, G. Ferrari, M.C. Fontana, E. Imbrogno, A. Padella, G. Simonetti, G. Pasquini, D. Cangini, B.M. Giannini, C. Cerchione, A. Santoro, J.M. Hernández-Rivas, D. Calistri, G. Castellani, E. Sabattini, N. Testoni, D. Remondini, G. Martinelli. HOW TO DETECT “3C-UP”, A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP. Hematologica Abstract Book October 2019 (SIE) Suppl.2
214. C. Cerchione, G. Martinelli, L. Catalano, N. Pugliese, A. Gravetti, D. Nappi, S. Ronconi, D. Cangini, M.B. Giannini, M. Altini, F. Pane, V. Martinelli. ROLE OF SEDOANALGESIA FOR PAIN ASSOCIATED WITH BONE MARROW ASPIRATION AND BONE BIOPSY. Hematologica Abstract Book October 2019 (SIE) Suppl.2
215. C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, M. Di Perna, K. Ferrara, S. Ronconi, D. Cangini, V. Di Battista, M. Ceccolini, M. Altini, F. Pane, L. Catalano. POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA. Hematologica Abstract Book October 2019 (SIE) Suppl.2
216. C. Cerchione, L. Catalano, S. Rocco, S. Palmieri, D. Nappi, A.E. Pareto, S. Ronconi, M. Ceccolini, G. Martinelli, F. Pane, F. Ferrara, BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA. Hematologica Abstract Book October 2019 (SIE) Suppl.2
217. M.B. Giannini, D. Cangini, C. Cerchione, V. Di Battista, A. Lucchesi, G. Musuraca, M. Ceccolini, R. Sonia, G. Martinelli. A RARE CASE OF HAIRY CELL LEUKEMIA IN ASSOCIATION WITH MAST-CELL LEUKEMIA. Hematologica Abstract Book October 2019 (SIE) Suppl.2
218. C. Cerchione, G. Martinelli, I. Soriente, A.M. D’Arco, P. Danise, G. Cerciello, V. Di Battista, D. Cangini, M.B. Giannini, F. Pane, F. Alfinito. ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES. Hematologica Abstract Book October 2019 (SIE) Suppl.2.
219. C. Cerchione, G. Martinelli, D. Nappi, A.E. Pareto, A. Lucchesi, G. Musuraca, S. Ronconi, F. Pane, L. Catalano. PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE. Hematologica Abstract Book October 2019 (SIE) Suppl.2.
220. M. Gentile, G. Specchia, D. Derudas, M. Galli, S. Rocco, C. Conticello, C. Califano, N. Giuliani, S. Mangiacavalli, E. Attingenti, A. Lombardo, M. Brunori, E. Rossi, E. Antonioli, R. Ria, R. Zambello, N. Di Renzo, G. Mele, G. Marcacci, P. Musto, S. Capalbo, N. Cascavilla, C. Cerchione, A. Belotti, C. Criscuolo, G. Uccello, P. Curci, E. Vigna, D. Vincelli, A. Bonalumi, A. Siniscalchi, R. Stocchi, M. Martino, S. Ballanti, D. Gangemi, A. Gagliardi, B. Gamberi, A. Pompa, A.G. Recchia, G. Tripepi, F. Frigeri, U. Consoli, S. Bringhen, E. Zamagni, F. Patriarca, V. De Stefano, F. Di Raimondo, F. Ferrara, F. Morabito, M.T. Petrucci, M. Offidani. ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE (ELORD) AS SALVAGE THERAPY FOR PATIENTS WITH MULTIPLE MYELOMA: ITALIAN, MULTICENTER, RETROSPECTIVE CLINICAL EXPERIENCE WITH 300 CASES OUTSIDE OF CONTROLLED CLINICAL TRIALS. Hematologica Abstract Book October 2019 (SIE) Suppl.2.
221. D. Cangini, C. Cerchione, M. B. Giannini, V. Di Battista, F. Frabetti, E. Petracci, S. Ronconi, G. Martinelli. HIGH-DOSE MELPHALAN IS A SAFE CONDITIONING REGIMEN IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA. Hematologica Abstract Book October 2019 (SIE) Suppl.2.
222. C. Cerchione, L. Catalano, G. Martinelli, S. Rocco, S. Palmieri, D. Nappi, A.E. Pareto, S. Ronconi, F. Pane, F. Ferrara, OLD/NEW IN NOVEL AGENTS' ERA: BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA. Leukemia & Myeloma 2019 (October 23-26, 2019, New York) – American Journal of Hematology Abstract book
223. C. Cerchione, O. Vitagliano, A.E. Pareto, D. Nappi, P. Danise, I. Soriente, G. Cerciello, F. Pane, F. Alfinito, Erythropoiesis stimulating agents (ESAs) in management of myelodysplastic syndromes: RECAMDS Trial. EHA-SWG Scientific Meeting on Red Cells, 7-9 November 2019, Madrid, Spain
224. Patrizia Mondello, MD PhD MSc , Irene Dogliotti, MD , Jan-Paul Bohn , Federica Cavallo , Simone Ferrero, MD , Barbara Botto , Claudio Cerchione, MD PhD , Davide Nappi , Sonya De Lorenzo , Giovanni Martinelli, MD , Dominik Wolf, Univ. Prof. Dr. , Giacomo Loseto, MD , Salvatore Cuzzocrea, MD PhD , Wolfgang Willenbacher, MD PhD , Michael Mian, MD. ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. Blood (2019) 134 (Supplement_1 - ASH 2019 Abstract Book): 1565.
225. Elisa Brilli, PhD, Michela Asperti, PhD, Annalisa Castagna, B.S., PhD, Claudio Cerchione, MD PhD, Domenico Girelli, MD, PhD, Maura Poli, PhD, Germano Tarantino. Effect of Oral Iron Treatment in Tmprss6 Knock-out Mouse Model

     Blood (2019) 134 (Supplement_1 – ASH 2019 Abstract book): 2235.

226. Claudio Cerchione, Lucio Catalano, Davide Nappi, Stefano Rocco, Salvatore Palmieri, Anna Emanuele Pareto, Gerardo Musuraca, Fabrizio Pane, Felicetto Ferrara, Giovanni Martinelli Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: Old/new in novel agents' era. DOI: 10.1177/0300891620953388
227. Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: Old/new in novel agents' era. DOI: 10.1200/JCO.2020.38.15_suppl.e20517 Journal of Clinical Oncology 38, no. 15_suppl
228. Davide Nappi, Lucio Catalano, Anna Emanuele Pareto, Gerardo Musuraca, Fabrizio Pane, Giovanni Martinelli, Claudio Cerchione, Carfilzomib-Lenalidomide-Dexamethasone in the management of Lenalidomide-refractory Multiple Myeloma. DOI: 10.1200/JCO.2020.38.15_suppl.e20517 Journal of Clinical Oncology 38, no. 15_suppl
229. Claudio Cerchione, Giovanni Martinelli, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, Alessandro Lucchesi, Fabrizio Pane, Lucio Catalano. Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone. DOI: 10.1200/JCO.2020.38.15_suppl.e20514 Journal of Clinical Oncology 38, no. 15_suppl
230. G. Marconi, A. Piciocchi, S. Capria, E. Audisio, E. Borlenghi, G. Priolo, M. Breccia, I. Urbino, G. Rossi, G. Simonetti,

     C. Papayannidis, E. Crea, C. Cerchione, R. M. Lemoli, F. Ciceri, V. Gaidano, A. Cignetti, P. Fazi, M. Vignetti, G. Martinelli

     SAFETY RUN-IN COHORT 1 OF GIMEMA AML1718: A SAFETY RUN-IN AND PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, CYRATABINE AND IDARUBICINE (V-FLAI) IN INDUCTION THERAPY OF ACUTE MYELOID LEUKEMIA

     HemaSphere, 2020;4:S1, Abstract Book, DOI: http://dx.doi.org/10.1097/HS9.0000000000000404

231. C. Cerchione, F. Alfinito, O. Vitagliano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, I. Soriente, C. Lilli, P. Danise, F. Pane, G. Martinelli

     ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES

     HemaSphere, 2020;4:S1, Abstract Book, DOI: http://dx.doi.org/10.1097/HS9.0000000000000404

232. C. Cerchione, L. Catalano, D. Nappi, A. E. Pareto, G. Musuraca, S. Ronconi, M. Ceccolini, A. Lucchesi, F. Pane, G. Martinelli

     CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

     HemaSphere, 2020;4:S1, Abstract Book, DOI: http://dx.doi.org/10.1097/HS9.0000000000000404

233. C. Cerchione, L. Catalano, S. Rocco, S. Palmieri, D. Nappi, A. E. Pareto, S. Ronconi, G. Musuraca, A. Lucchesi, M. Ceccolini, F. Pane, F. Ferrara, G. Martinelli

     BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS‘ ERA

     HemaSphere, 2020;4:S1, Abstract Book, DOI: http://dx.doi.org/10.1097/HS9.0000000000000404

234. C. Cerchione, L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Frabetti, F. Pane, G. Martinelli

     POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

     HemaSphere, 2020;4:S1, Abstract Book, DOI: http://dx.doi.org/10.1097/HS9.0000000000000404

235. C. Cerchione L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Mammoli, F. Pane, G. Martinelli

     PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE

     MYELOMA IN TREATMENT WITH POMALIDOMIDEDEXAMETHASONE

     HemaSphere, 2020;4:S1, Abstract Book, DOI: http://dx.doi.org/10.1097/HS9.0000000000000404

236. C. Cerchione, F. Alfinito, O. Vitagliano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, I. Soriente, C. Lilli, P. Danise, F. Pane, G. Martinelli

     ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES

     Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020

237. C. Cerchione, L. Catalano, D. Nappi, A. E. Pareto, G. Musuraca, S. Ronconi, M. Ceccolini, A. Lucchesi, F. Pane, G. Martinelli

     CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

     Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020

238. C. Cerchione, L. Catalano, S. Rocco, S. Palmieri, D. Nappi, A. E. Pareto, S. Ronconi, G. Musuraca, A. Lucchesi, M. Ceccolini, F. Pane, F. Ferrara, G. Martinelli

     BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS‘ ERA

     Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020

239. C. Cerchione, L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Frabetti, F. Pane, G. Martinelli

     POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

     Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020

240. C. Cerchione L. Catalano, D. Nappi, A. E. Pareto, D. Cangini, M. B. Giannini, V. Di Battista, F. Mammoli, F. Pane, G. Martinelli

     PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE

     MYELOMA IN TREATMENT WITH POMALIDOMIDEDEXAMETHASONE

     Clinical Lymphoma, Myeloma & Leukemia Vol. 20 Suppl. 1 SOHO 2020

241. C. Cerchione, L. Catalano, D. Nappi, A.E. Pareto, G. Musuraca, A. Lucchesi, S. Ronconi, M. Ceccolini, D. Cangini, M.B. Giannini, V. Di Battista, G. Simonetti, A. Ferrari, M.T. Bochicchio, A. Ghelli Luserna di Rorà, M. Ghetti, R. Napolitano, M.C. Fontana, A. Padella, F. Pane, G. Martinelli

     PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE

     Hematologica Abstract Book October 2020 (SIES) Suppl.2. https://doi.org/10.3324/haematol.2020.s2

242. C. Cerchione, F. Alfinito, I. Soriente, A.M. D’Arco, P. Danise, G. Cerciello, G. Musuraca, A. Lucchesi, V. Di Battista, D. Cangini, M.B. Giannini, S. Ronconi, M. Ceccolini, F. Pane, G. Martinelli

     ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES

     Hematologica Abstract Book October 2020 (SIES) Suppl.2. https://doi.org/10.3324/haematol.2020.s2

243. C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, A.E. Pareto, M. Di Perna, K. Ferrara, S. Ronconi, M. Ceccolini, D. Cangini, M.B. Giannini, V. Di Battista, G. Simonetti, A. Ferrari, M.T. Bochicchio, A. Ghelli Luserna di Rorà, M. Ghetti, R. Napolitano, M.C. Fontana, A. Padella, F. Pane, G. Martinelli

     CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

     Hematologica Abstract Book October 2020 (SIES) Suppl.2. https://doi.org/10.3324/haematol.2020.s2

244. C. Cerchione, L. Catalano, D. Nappi, A.E. Pareto, G. Musuraca, A. Lucchesi, S. Ronconi, M. Ceccolini, D. Cangini, M.B. Giannini, V. Di Battista, G. Simonetti, A. Ferrari, M.T. Bochicchio, A. Ghelli Luserna di Rorà, M. Ghetti, R. Napolitano, M.C. Fontana, A. Padella, F. Pane, G. Martinelli

     POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

     Hematologica Abstract Book October 2020 (SIES) Suppl.2. https://doi.org/10.3324/haematol.2020.s2

245. C. Cerchione, L. Catalano, D. Nappi, S. Rocco, S. Palmieri, A. Pareto, F. Pane, F. Ferrara, G. Martinelli

     Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era

     Hematol transfus cell ther. 2020;42(S 1)

246. C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, A. Pareto, F. Pane, G. Martinelli

     Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma

     Hematol transfus cell ther. 2020;42(S 1)

247. C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, F. Pane, G. Martinelli

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

Hematol transfus cell ther. 2020;42(S 1)

Book Chapters:

Mieloma Multiplo - Registro tumori della Romagna – I tumori maligni in Romagna (2019, Maggioli Editore)

Books:

Manuale di Ematologia – AIMS (Associazione Italiana Medici Specializzandi) Edizione 2023 – First Author